var docs;if (!docs) docs =[]; docs["97"]={"9700":"<p><b>Title</b> Eluxadoline / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Eluxadoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Decrease the eluxadoline dose to 75 mg twice daily if combined antihepaciviral combination products. Monitor patients for increased eluxadoline effects/toxicities (eg, impaired mental or physical abilities needed to drive a car or operate machinery, constipation, abdominal pain).</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 30 healthy volunteers, cyclosporine (600 mg single oral dose) increased the eluxadoline (100 mg single oral dose) AUC and maximum serum concentration 4.4- and 6.2-fold, respectively.<sup>1,2</sup> During treatment with cyclosporine, 6 (20%) patients reported adverse events while only 2 (7%) patients reported adverse events during treatment with eluxadoline alone.<sup>1</sup><br><br>Eluxadoline prescribing information states that the eluxadoline dose should be reduced to 75 mg twice daily if used with OATP1B1/SLCO1B1 inhibitors, specifically listing ritonavir (a component of antihepaciviral combination products) as one such inhibitor.<sup>2</sup> Patients should also be monitored for increased eluxadoline adverse effects.<sup>2</sup><br><br>The likely mechanism of this interaction is cyclosporine inhibition of the OATP1B1/SLCO1B1 transporter. This transporter is thought to be primarily responsible for eluxadoline uptake into the liver to allow for substantial first pass metabolism.<sup>1,2</sup> Cyclosporine inhibition of the MRP2 or BSEP transporters may also play a role. Some in vitro data suggest that ritonavir may inhibit OATP1B1/SLCO1B1,<sup>3,4,5</sup> while 1 clinical study suggests little to no inhibition by ritonavir.<sup>6</sup> The paritaprevir component of antihepaciviral combination products has also been shown to inhibit OATP1B1/SLCO1B1.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. <i>J Clin Pharmacol</i>. 2015;55(5):534-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25491493\">[PubMed 25491493]</a></p>\n<p>2. Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.</p>\n<p>3. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. <i>Xenobiotica</i>. 2010;40(3):163-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102298\">[PubMed 20102298]</a></p>\n<p>4. Izumi S, Nozaki Y, Komori T, et al. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17beta-glucuronide, estrone-3-sulfate, and sulfobromophthalein. <i>Drug Metab Dispos</i>. 2013;41(10):1859-1866. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23920221\">[PubMed 23920221]</a></p>\n<p>5. Shitara Y, Takeuchi K, Horie T. Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. <i>J Pharm Sci</i>. 2013;102(9):3427-3435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23440887\">[PubMed 23440887]</a></p>\n<p>6. Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. <i>J Clin Pharmacol</i>. 2012;52(11):1725-1738. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22174437\">[PubMed 22174437]</a></p>\n<p>7. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>8. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9701":"<p><b>Title</b> Levocetirizine / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Levocetirizine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. The clinical relevance of the possible increase in levocetirizine concentrations/exposure with ritonavir and/or ritonavir-containing products is uncertain.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> Data regarding this potential interaction come from one study with cetirizine, the racemic mix of both dextro- and levocetirizine.In an open-label crossover study, 17 subjects received cetirizine alone (10mg/day x 4 days), ritonavir alone (300mg twice daily titrated to 600mg twice daily for at least 7 days), and cetirizine plus ritonavir (10mg/day and 600mg twice daily, respectively, x 4 days).<sup>1</sup> Compared to cetirizine alone, when combined with ritonavir cetirizine AUC increased by 42%, clearance decreased by 29%, and elimination half-life increased by 53%. Despite these significant changes, none of the 16 subjects completing the study (1 dropped out after the cetirizine alone arm) reported any adverse effects while receiving the combination. Longer term clinical consequences of such increased exposure to cetirizine are unclear, but considering the safety profile of cetirizine (particularly in other populations where concentrations/AUC are increased), serious adverse effects would not be expected.<br><br>The mechanism of this apparent interaction is unclear. Ritonavir is a potent inhibitor of drug metabolizing enzymes, such as CYP3A4, but cetirizine is only minimally metabolized<sup>2</sup> making inhibition of metabolism unlikely to fully explain the observed changes. Ritonavir is also an inhibitor of certain drug transporters, such as the efflux transporter P-glycoprotein, and considering that cetirizine is a P-glycoprotein substrate,<sup>3</sup> it is possible that ritonavir inhibition of cetirizine tubular secretion could explain this apparent interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Peytavin G, Gautran C, Otoul C, et al. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. <i>Eur J Clin Pharmacol</i>. 2005;61(4):267-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15889300\">[PubMed 15889300]</a> </p>\n<p>2. Wood SG, John BA, Chasseaud LF, Yeh J, Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. <i>Ann Allergy</i>. 1987;59(6 pt 2):31-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2892447\">[PubMed 2892447]</a> </p>\n<p>3. Polli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. <i>J Pharm Sci</i>. 2003;92(10):2082-2089. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14502547\">[PubMed 14502547]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9702":"<p><b>Title</b> Valsartan / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Valsartan. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> While the mechanism and clinical significance of this potential interaction have not been established, consider (per antihepaciviral combination product US prescribing information) decreasing the valsartan dose and monitoring for evidence of hypotension and worsening renal function when these agents are used in combination. Similar recommendations are provided for use of antihepaciviral combination products with losartan or candesartan, but not for use with other angiotensin receptor blockers (eg, azilsartan, irbesartan, olmesartan, telmisartan).</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> The hepatic uptake and efflux of valsartan has been shown to be at least partially dependent on SLCO/OATP1B1, SLCO/OATP1B3, and MRP2 (ABCC2).<sup>1</sup> Valsartan prescribing information states that inhibitors of these transporters may increase serum concentrations of valsartan.<sup>2</sup> Ritonavir is listed as an MRP2 inhibitor,<sup>2</sup> and paritaprevir has been shown to inhibit SLCO/OATP1B1 and SLCO/OATP1B3.<sup>3,4</sup><br><br>The extent to which inhibition of these transporters would impact valsartan has not been established, particularly in the absence of studies or case reports of this hypothesized interaction. Similarly, the relatively wide therapeutic index of valsartan makes the clinical significance of even a modest pharmacokinetic interaction unclear. However, US prescribing information for antihepaciviral combination products recommends valsartan dose reduction and additional monitoring if these agents are used in combination.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. <i>Drug Metab Dispos</i>. 2006;34(7):1247-1254. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16624871\">[PubMed 16624871]</a></p>\n<p>2. Diovan (valsartan) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2010.</p>\n<p>3. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2016.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9703":"<p><b>Title</b> Clarithromycin / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Clarithromycin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid clarithromycin doses greater than 1000 mg/day in patients taking antihepaciviral combination products. Patients with impaired renal function who are receiving concomitant clarithromycin and ritonavir (a component of antihepaciviral combination products) should have their clarithromycin dose adjusted as follows: Cl<sub>cr</sub> 30-60 mL/min, reduce clarithromycin dose by 50%; Cl<sub>cr</sub> &lt;30 mL/min, reduce clarithromycin dose by 75%. Also, consideration should be given to alternative antibiotic therapy for infections other than those due to <i>Mycobacterium avium</i>. For all patients receiving concomitant therapy with clarithromycin and ritonavir, monitor for toxic effects of clarithromycin, including the potential for QT interval prolongation and the development of ventricular arrhythmias.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> Ritonavir (200 mg every 8 hours) increased the clarithromycin AUC by an average of 77% and nearly completely inhibited formation of the active 14-hydroxy-clarithromycin metabolite in a study of 22 healthy volunteers.<sup>1</sup> Darunavir/ritonavir (400 mg/100 mg twice daily x 7 days) increased clarithromycin AUC by an average of 57% in 17 healthy volunteers and decreased the AUC of 14-hydroxy-clarithromycin to below the limit of quantitation.<sup>2</sup> Similarly, combination tipranavir/ritonavir increased clarithromycin AUC by an average of 19% and decreased the 14-hydroxy-clarithromycin AUC by more than 90% in a study of 24 healthy volunteers.<sup>3</sup> These effects on the 14-hydroxy active metabolite is of potentially significant clinical importance as this metabolite is thought to account for a considerable portion of the total clarithromycin activity against <i>H. influenzae</i>.<sup>4,5</sup><br><br>The metabolism of clarithromycin (to its 14-hydroxy metabolite) is likely inhibited by ritonavir (and other protease inhibitors) via their inhibition of CYP3A4. Increased clarithromycin concentrations can increase the risk of drug-induced QT-prolongation and the development of life-threatening ventricular arrhythmias. According to clarithromycin prescribing information, doses greater than 1000 mg per day should not be administered to patients who are receiving ritonavir.<sup>5</sup> Also, decreased concentrations of the active 14-hydroxy-clarithromycin metabolite may negatively impact its effectiveness against certain organisms.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. <i>Clin Pharmacol Ther</i>. 1998;64(4):355-362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9797791\">[PubMed 9797791]</a></p>\n<p>2. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. <i>J Clin Pharmacol</i>. 2008;48(1):60-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094220\">[PubMed 18094220]</a></p>\n<p>3. Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. <i>Pharmacotherapy</i>. 2007;27(6):888-909. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17542771\">[PubMed 17542771]</a></p>\n<p>4. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. <i>Antimicrob Agents Chemother</i>. 1990;34(7):1407-1413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2143642\">[PubMed 2143642]</a></p>\n<p>5. Vallee E, Azoulay-Dupuis E, Swanson R, Bergogne-Berezin E, Pocidalo JJ. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. <i>J Antimicrob Chemother</i>. 1991;27 (suppl A):31-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827100\">[PubMed 1827100]</a></p>\n<p>6. Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: Abbott Laboratories; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9704":"<p><b>Title</b> Desmopressin / Tolvaptan</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tolvaptan may diminish the therapeutic effect of Desmopressin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of tolvaptan and desmopressin.</p> \n<p><b>Discussion</b> A published case report describes a 42-year-old man with autosomal dominant polycystic kidney disease and low blood von Willebrand factor (VWF) antigen, VWF ristocetin cofactor activity, and factor VIII cofactor activity who received desmopressin both before and during tolvaptan (60 mg orally every morning and 30 mg orally every evening) treatment.<sup>1</sup> Desmopressin more than doubled VWF antigen, VWF ristocetin cofactor activity, and factor VIII activity in the absence of tolvaptan, but was associated with no substantial change in any of these during tolvaptan treatment.<br><br>The suspected primary mechanism of interaction between these agents is tolvaptan inhibition of vasopressin 2 receptor agonism by desmopressin. US and Canadian tolvaptan labeling recommends against use with desmopressin.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Blumenfeld JD, Tepler J, Mauer A, Coller B, Bichet DG, Smith B. Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease. <i>Blood</i>. 2011;118(2):474-476. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21757630\">[PubMed 21757630]</a></p>\n<p>2. Samsca (tolvaptan) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; February 2014.</p>\n<p>3. Jinarc (tolvaptan) [product monograph]. Saint-Laurent, QC, Canada: Otsuka Canada Pharmaceutical Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9705":"<p><b>Title</b> Methemoglobinemia Associated Agents / Dapsone (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapsone (Topical) may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when topical dapsone is used in combination with other agents associated with development of methemoglobinemia.</p>\n<div>\n <p><b>Methemoglobinemia Associated Agents Interacting Members</b> Acetaminophen, Amyl Nitrite, Benzocaine, Celecoxib, Chloroquine, Dapsone (Systemic), Dapsone (Topical), Flutamide, Isosorbide Dinitrate, Isosorbide Mononitrate, Lidocaine (Systemic), Lidocaine (Topical), Mafenide, Metoclopramide, Nicorandil, Nitric Oxide, Nitrofurantoin, Nitroglycerin, Nitroprusside, Phenazopyridine, PHENobarbital, Phenytoin, Prilocaine, Primaquine, Propacetamol, QuiNINE, Sodium Nitrite, SulfADIAZINE, Sulfamethoxazole, SulfaSALAzine, Tetracaine (Topical), Zopiclone</p>\n</div> \n<p><b>Discussion</b> The prescribing information for topical dapsone warns about the potential for development of methemoglobinemia during treatment, particularly when used in combination with other methemoglobinemia associated agents.<sup>1</sup> According to the prescribing information, methemoglobinemia has been reported with use of topical dapsone.<sup>1</sup> Patients at increased risk of clinically significant methemoglobinemia include those with glucose-6-phosphate deficiencies and those with congenital or idiopathic methemoglobinemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aczone (dapsone) gel [prescribing information]. Irvine, CA: Allergan, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9706":"<p><b>Title</b> Estazolam / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estazolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased estazolam effects/toxicities if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Product labeling for estazolam states that in vitro studies have found estazolam to be a substrate of CYP3A4, and that strong inhibitors of CYP3A4 would be expected to increase estazolam concentrations and effects.<sup>1</sup><br><br>In contrast to the in vitro data suggesting that estazolam relies on CYP3A4 for a significant portion of its metabolism,<sup>1,2</sup> a pharmacokinetic study of 10 health volunteers found that coadministration of the strong CYP3A4 inhibitor itraconazole (100 mg daily on days 1 to 7) and estazolam (4 mg single dose on day 4) had no effect on the pharmacokinetics of estazolam.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Estazolam [prescribing information]. Sellersville, PA: Teva Pharmaceuticals Inc; June 2008.</p>\n<p>2. Miura M, Otani K, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. <i>Xenobiotica</i>. 2005;35(5):455-465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16012077\">[PubMed 16012077]</a></p>\n<p>3. Otsuji Y, Okuyama N, Aoshima T, et al. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. <i>Ther Drug Monit</i>. 2002;24(3):375-378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021628\">[PubMed 12021628]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9707":"<p><b>Title</b> Dolutegravir / Rilpivirine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rilpivirine may increase the serum concentration of Dolutegravir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to data in the dolutegravir prescribing information, the dolutegravir AUC and minimum serum concentration were an average of 12% and 22% higher, respectively, in a study of 16 subjects who received concurrent rilpivirine 25 mg/day and dolutegravir 50 mg/daily.<sup>1</sup> The rilpivirine AUC was non-significantly increased, and according to the dolutegravir labeling, the interaction is unlikely to be of clinical relevance.<br><br>The specific mechanism by which dolutegravir concentrations were increased is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9708":"<p><b>Title</b> Etoposide Phosphate / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate. If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study of children receiving chemotherapy prior to autologous hematopoietic stem cell transplantation for treatment-refractory or relapsed solid tumors, the median clearance of intravenous etoposide (960-1500 mg/m2) was approximately 1.8-fold greater in 7 patients receiving enzyme inducing antiepileptic drugs (phenobarbital [n=5], phenytoin [n=1]l, or phenobarbital and phenytoin [n=1]) than in 22 patients not receiving these enzyme inducing drugs.<sup>1</sup> The suspected primary mechanism of interaction between these agents is induction of CYP3A4-mediated etoposide metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. <i>J Clin Oncol</i>. 1994;12(11):2390-2397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7964955\">[PubMed 7964955]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9709":"<p><b>Title</b> Etoposide / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If these combinations cannot be avoided, monitor patients closely for diminished etoposide response.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital*, Phenytoin*, Primidone, RifAMPin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of children receiving chemotherapy prior to autologous hematopoietic stem cell transplantation for treatment-refractory or relapsed solid tumors, the median clearance of intravenous etoposide (960 to 1500 mg/m2) was approximately 1.8-fold greater in 7 patients receiving enzyme-inducing antiepileptic drugs (phenobarbital [n = 5], phenytoin [n = 1], or phenobarbital and phenytoin [n = 1]) than in 22 patients not receiving these enzyme inducing drugs.<sup>1</sup> The suspected primary mechanism of interaction between these agents is induction of CYP3A4-mediated etoposide metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. <i>J Clin Oncol</i>. 1994;12(11):2390-2397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7964955\">[PubMed 7964955]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9710":"<p><b>Title</b> Vitamin K Antagonists / Etoposide Phosphate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Etoposide Phosphate may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased INR/warfarin effects if etoposide is initiated.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Case reports describe increased anticoagulation in warfarin-stable patients following the addition of etoposide-containing regimens.<sup>1,2</sup> In one case a patient's INR increased approximately sixfold within 16 days of starting etoposide and carboplatin.<sup>1</sup> In another case a patient's PT increased 8-15 seconds after receiving etoposide and vindesine.<sup>2</sup> This second case occurred again upon rechallenge. The mechanism of this apparent interaction is unclear. Etoposide has been reported to inhibit CYP2C8 and 3A4 isoenzymes. Inhibiting either isoenzyme could result in decreased warfarin clearance, and increased effects. Acenocoumarol is not affected by these enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Le AT, Hasson NK, and Lum BL, “Enhancement of Warfarin Response in a Patient Receiving Etoposide and Carboplatin Chemotherapy,” <i>Ann Pharmacother</i>, 1997, 31:1006-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9296241\">[PubMed 9296241]</a></p>\n<p>2. Ward K and Bitran JD, “Warfarin, Etoposide and Vindesine Interactions,” <i>Cancer Treat Rep</i>, 1984, 68:817-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6539172\">[PubMed 6539172]</a></p>\n<p>3. Desai PB, Duan JZ, Zhu YW, et al, “Human Liver Microsomal Metabolism of Paclitaxel and Drug Interactions,” <i>Eur J Drug Metab Pharmacokinet</i>, 1998, 23(3):417-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9842986\">[PubMed 9842986]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9711":"<p><b>Title</b> Etoposide Phosphate / Echinacea</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Echinacea may increase the serum concentration of Etoposide Phosphate. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased etoposide effects/toxicity when used together with echinacea.</p> \n<p><b>Discussion</b> A published case report describes a 61-year-old man with non-small cell lung cancer who experienced profound thrombocytopenia, requiring platelet transfusion, following his first cycle of treatment with cisplatin and etoposide.<sup>1</sup> It was subsequently discovered that the patient had been self-treating with echinacea, which was discontinued prior to the second chemotherapy cycle. Following this second cycle, the patient again experienced thrombocytopenia but to a lesser degree that did not require any platelet transfusion. The authors of the report theorized that this severe initial thrombocytopenia was the result of an interaction between echinacea and etoposide, where the echinacea inhibited the CYP3A-mediated metabolism of etoposide, leading to greater etoposide concentrations and effects.<sup>1</sup><br><br>The degree to which echinacea is capable to altering CYP3A activity is unclear. Several studies have evaluated this effect in vitro and in vivo, resulting in largely discrepant findings. Echinacea treatment (500 mg three times/day for 14 days with lopinavir/ritonavir and 14 days alone) was associated with an average 27% decrease in midazolam AUC (as a marker of CYP3A activity) and an average 37% increase in the midazolam oral clearance in a study of 13 healthy volunteers, suggesting that echinacea increased CYP3A activity.<sup>2</sup> Somewhat similarly, echinacea treatment (400 mg four times/day for 8 days) was associated with an average 23% decrease in midazolam AUC and an average 34% increase in midazolam clearance following IV administration of midazolam.<sup>3</sup> However, the oral clearance of midazolam was not significantly altered, with additional analysis suggesting that echinacea increased hepatic metabolism of midazolam but inhibited intestinal metabolism of oral midazolam. In vitro studies have also largely found mixed evidence for relatively weak-moderate CYP3A induction and inhibition.<sup>4,5,6</sup><br><br>Given this case report and the variable evidence for echinacea-mediated CYP3A induction and/or inhibition, caution would be prudent with concurrent use of any CYP3A substrate (and particularly with agents that have a narrow therapeutic index).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bossaer JB, Odle BL, “Probable Etoposide Interaction with Echinacea,” <i>J Diet Suppl</i>, 2012, 9(2):90-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22607644\">[PubMed 22607644]</a></p>\n<p>2. Penzak SR, Robertson SM, Hunt JD, et al, “Echinacea Purpurea Significantly Induces Cytochrome P450 3A Activity But Does Not Alter Lopinavir-Ritonavir Exposure in Healthy Subjects,” <i>Pharmacotherapy</i>, 2010, 30(8):797-805. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653355\">[PubMed 20653355]</a></p>\n<p>3. Gorski JC, Huang SM, Pinto A, et al, “The Effect of Echinacea (Echinacea Purpurea Root) on Cytochrome P450 Activity In Vivo,” <i>Clin Pharmacol Ther</i>, 2004, 75(1):89-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14749695\">[PubMed 14749695]</a></p>\n<p>4. Hansen TS, Nilsen OG, “In Vitro CYP3A4 Metabolism: Inhibition by Echinacea Purpurea and Choice of Substrate for the Evaluation of Herbal Inhibition,” <i>Basic Clin Pharmacol Toxicol</i>, 2008, 103(5):445-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18947363\">[PubMed 18947363]</a></p>\n<p>5. Gurley BJ, Gardner SF, Hubbard MA, et al, “In Vivo Assessment of Botanical Supplementation on Human Cytochrome P450 Phenotypes: Citrus Aurantium, Echinacea Purpurea, Milk Thistle, and Saw Palmetto,” <i>Clin Pharmacol Ther</i>, 2004, 76(5):428-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15536458\">[PubMed 15536458]</a></p>\n<p>6. Yale SH, Glurich I, “Analysis of the Inhibitory Potential of Ginkgo Biloba, Echinacea Purpurea, and Serenoa Repens on the Metabolic Activity of Cytochrome P450 3A4, 2D6, and 2C9,” <i>J Altern Complement Med</i>, 2005, 11(3):433-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15992226\">[PubMed 15992226]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9712":"<p><b>Title</b> Ioflupane I 123 / Cocaine (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cocaine (Topical) may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent use of cocaine in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of cocaine prior to ioflupane administration may minimize the interference is unknown.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and, to a lesser extent, the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> As summarized in a review on the topic, several investigations have demonstrated that cocaine use blocks DAT (chronic use may also upregulate DAT expression), significantly altering DAT imaging.<sup>2</sup><br><br>Although the ioflupane prescribing information does not specifically recommend avoidance of cocaine for imaging,<sup>1</sup> others have recommended cocaine discontinuation for at least 5 half-lives prior to ioflupane administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. DaTscan (ioflupane) [prescribing information]. Arlington Heights, IL: GE Healthcare Medi-Physics Inc; April 2011.</p>\n<p>2. Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. <i>Eur J Nucl Med Mol Imaging</i>. 2008;35(2):424-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9713":"<p><b>Title</b> Cimetropium / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of cimetropium with other drugs that have anticholinergic properties. If these combinations can not be avoided, monitor patients closely for evidence of anticholinergic-related toxicities (eg, urinary retention, constipation, tachycardia, dry mouth).</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Cimetropium prescribing information states that concurrent use of other anticholinergic drugs should be avoided due to the risk for additive/excessive anticholinergic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Algiron (cimetropium) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200900846. Accessed January 12, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9714":"<p><b>Title</b> Cimetropium / Cholinergic Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cholinergic Agonists may diminish the anticholinergic effect of Cimetropium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced therapeutic effect of cimetropium if combined with a cholinergic agonist. Any desired cholinergic effects may also be reduced with the use of cimetropium.</p>\n<div>\n <p><b>Cholinergic Agonists Interacting Members</b> Bethanechol, Cevimeline, Choline Alfoscerate, Guanidine, Methacholine, Pilocarpine (Systemic)<br><b>Exceptions</b> Acetylcholine, Carbachol, Pilocarpine (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> The effects of cimetropium and cholinergic agonists oppose each other (one blocks the effects of acetylcholine while the other enhances it), which may result in a diminished therapeutic effect. Product labeling for cimetropium states that use of cimetropium with cholinergic agents may decrease or eliminate the therapeutic effect of cimetropium.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Algiron (cimetropium) tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200900846. Accessed January 12, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9715":"<p><b>Title</b> Gastrointestinal Agents (Prokinetic) / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effectiveness of prokinetic agents when combined with anticholinergic agents. Agents with greater systemic anticholinergic effects are likely of more concern than agents with lesser effects.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n <p><b>Gastrointestinal Agents (Prokinetic) Interacting Members</b> Bromopride, Cisapride, Metoclopramide, Mosapride</p>\n</div> \n<p><b>Discussion</b> Product labeling for metoclopramide and mosapride states that the effects of these agents on gastrointestinal motility may be antagonized by anticholinergic agents.<sup>1,2,3</sup> US prescribing information for at least two anticholinergic agents also states that anticholinergic agents may antagonize the effects of prokinetic agents.<sup>4,5</sup><br><br>These agents exert opposing effects on gastric motility, thus intended prokinetic effects may be diminished with the use of anticholinergic agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</p>\n<p>2. Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011.</p>\n<p>3. Gasmotin (mosapride) tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200100565. Accessed May 1, 2015. </p>\n<p>4. Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015.</p>\n<p>5. Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9716":"<p><b>Title</b> Talniflumate / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aspirin may enhance the adverse/toxic effect of Talniflumate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible, consider alternatives to this combination. Concurrent use is generally not recommended.</p> \n<p><b>Discussion</b> The labeling for talniflumate cautions that concurrent use of talniflumate and aspirin is generally not recommended due to both the possible increased risk of gastrointestinal toxicity and the lack of evidence that aspirin can decrease any increased risk of cardiovascular events associated with the use of nonsteroidal anti-inflammatory drugs.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Somalgin (talniflumate) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198500515 . Accessed November 12, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9717":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Talniflumate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Talniflumate may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of talniflumate with other nonsteroidal anti-inflammatory agents.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The labeling for talniflumate states that it is advisable to avoid concurrent use of other anti-inflammatory analgesics.<sup>1</sup> The likely rationale for this recommendation is the possible increased risk of gastrointestinal and other toxicities associated with the use of nonsteroidal anti-inflammatory drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Somalgin (talniflumate) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198500515 . Accessed November 12, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9718":"<p><b>Title</b> Digoxin / Vemurafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Vemurafenib may increase the serum concentration of Digoxin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of vemurafenib and digoxin when possible. If concomitant use cannot be avoided, consider digoxin dose reduction.</p> \n<p><b>Discussion</b> In a clinical study summarized in vemurafenib US prescribing information, coadministration of vemurafenib (960 mg twice daily for 22 days) increased the digoxin (0.25 mg single dose) maximum concentration and AUC by 1.5- and 1.8-fold, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is vemurafenib inhibition of P-glycoprotein-mediated digoxin efflux.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9719":"<p><b>Title</b> Phosphodiesterase 5 Inhibitors / Molsidomine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Molsidomine may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Molsidomine should not be used with phosphodiesterase 5 (PDE5) inhibitors and is contraindicated in the labeling for at least one product due to the risk for excessive hypotension.</p>\n<div>\n <p><b>Phosphodiesterase 5 Inhibitors Interacting Members</b> Avanafil, Mirodenafil, Sildenafil, Tadalafil, Udenafil, Vardenafil</p>\n</div> \n<p><b>Discussion</b> According to the labeling for molsidomine, molsidomine should not be used with phosphodiesterase 5 (PDE5) inhibitors due to the risk for excessive hypotension,<sup>1,2</sup> and at least one product specifically lists the combination as contraindicated.<sup>1</sup><br><br>Both molsidomine and PDE5 inhibitors exert their effects through potentiation of the vasodilatory effects of cGMP -- molsidomine by stimulating cGMP production (via release of nitric oxide), and PDE5 inhibitors by inhibiting an enzyme responsible for the metabolism of cGMP. This overlapping effect is likely responsible for the labeled warning to avoid this combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Molsidain (molsidomine) [summary of product characteristics]. Barcelona, Spain; Sanofi-Aventis SA; August 2013.</p>\n<p>2. Molsiton (molsidomine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501832. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9721":"<p><b>Title</b> Vasodilators (Organic Nitrates) / Molsidomine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Molsidomine may enhance the hypotensive effect of Vasodilators (Organic Nitrates). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution when molsidomine is combined with other drugs that have the potential to decrease blood pressure, such as organic nitrates, and monitor patients closely for evidence of excessive blood pressure reduction, including evidence of orthostatic hypotension.</p>\n<div>\n <p><b>Vasodilators (Organic Nitrates) Interacting Members</b> Isosorbide Dinitrate, Isosorbide Mononitrate, Nicorandil, Nitroglycerin</p>\n</div> \n<p><b>Discussion</b> According to the labeling for molsidomine, concurrent use of molsidomine with other drugs that have the potential to decrease blood pressure, such as organic nitrates, may result in enhanced blood pressure-lowering effects.<sup>1,2</sup> Molsidomine works as a nitric oxide donor, encouraging vasodilation and possibly enhancing hypotensive effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Molsidain (molsidomine) [summary of product characteristics]. Barcelona, Spain; Sanofi-Aventis SA; August 2013.</p>\n<p>2. Molsiton (molsidomine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501832. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9722":"<p><b>Title</b> Alcohol (Ethyl) / Molsidomine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Molsidomine may enhance the hypotensive effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution when molsidomine is combined with other drugs that can lower blood pressure, such as alcohol, and monitor patients closely for evidence of excessive blood pressure reduction, including evidence of orthostatic hypotension.</p> \n<p><b>Discussion</b> According to the labeling for molsidomine, concurrent use of molsidomine with alcohol may result in enhanced blood pressure-lowering effects.<sup>1,2</sup> Molsidomine works as a nitric oxide donor, encouraging vasodilation and possibly enhancing hypotensive effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Molsidain (molsidomine) [summary of product characteristics]. Barcelona, Spain; Sanofi-Aventis SA; August 2013.</p>\n<p>2. Molsiton (molsidomine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501832. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9723":"<p><b>Title</b> Ranolazine / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased ranolazine effects/toxicities if combined with a P-glycoprotein inhibitor.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> The ranolazine prescribing information states that in vitro, ranolazine has been shown to be a P-glycoprotein (P-gp) substrate and concomitant use of drugs that inhibit P-gp may result in increased ranolazine exposure and effects.<sup>1</sup> The dose of ranolazine should be titrated based on clinical response.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9724":"<p><b>Title</b> P-glycoprotein/ABCB1 Substrates / Ranolazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ranolazine may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of P-glycoprotein substrates if combined with ranolazine.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Substrates Interacting Members</b> Afatinib, Aliskiren, Amiodarone, AtorvaSTATin, Betrixaban, Bilastine, Brentuximab Vedotin, Carfilzomib, Carvedilol, Celiprolol, Ceritinib, Cetirizine (Systemic), Cimetidine, Colchicine, Crizotinib, CycloSPORINE (Systemic), Dabigatran Etexilate, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Desloratadine, Dexamethasone (Systemic), Digitoxin, Digoxin, DilTIAZem, DOCEtaxel, DOXOrubicin (Conventional), Edoxaban, Erythromycin (Systemic), Estradiol (Systemic), Estradiol (Topical), Etoposide, Etoposide Phosphate, Everolimus, Fexofenadine, Fosamprenavir, Hydrocortisone (Systemic), IDArubicin, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Ivermectin (Systemic), Lapatinib, Ledipasvir, Linagliptin, Loperamide, Loperamide Oxide, Loratadine, Lovastatin, Methotrexate, MitoMYcin (Systemic), Morphine (Liposomal), Morphine (Systemic), Nadolol, Naldemedine, Naloxegol, Nelfinavir, NiCARdipine, Nintedanib, Ondansetron, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Paliperidone, PAZOPanib, QuiNIDine, QuiNINE, RaNITIdine, Ranolazine, RifAMPin, Riociguat, RisperiDONE, Ritonavir, RomiDEPsin, Saquinavir, SAXagliptin, Silodosin, Sirolimus, SITagliptin, Sofosbuvir, Tacrolimus (Systemic), Telaprevir, Temsirolimus, Teniposide, Tolvaptan, Trabectedin, Vemurafenib, Venetoclax, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ranolazine prescribing information, the concomitant administration of digoxin (0.125 mg daily ) and ranolazine (1000 mg twice daily) increased digoxin concentrations by 50%.<sup>1</sup><br><br>Ranolazine prescribing information states that drugs transported by P-glycoprotein (eg, digoxin) may require dose reductions when combined with ranolazine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9725":"<p><b>Title</b> Ranolazine / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of ranolazine and moderate CYP3A4 inducers. Use of ranolazine and CYP3A4 inducers is listed as a contraindication in the ranolazine prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Data described in the ranolazine product labeling show that coadministration of the strong CYP3A4 inducer rifampin (600mg daily) and ranolazine (1000mg twice daily) resulted in a 95% decrease in ranolazine plasma concentrations.<sup>1</sup> Although studies with moderate CYP3A inducers have not yet been conducted, product labeling recommends avoiding the concomitant use of ranolazine and CYP3A4 inducers.<sup>1</sup><br><br>Although the mechanism of this interaction has not been fully established, it is suspected that induction of CYP3A-mediated metabolism of ranolazine by rifampin (or other inducers) is primarily responsible.<sup>1</sup> Induction of p-glycoprotein-mediated transport (resulting in impaired absorption and enhanced elimination) of ranolazine by rifampin (or other inducers) has also been mentioned as a possible contributing mechanism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9726":"<p><b>Title</b> Cysteamine (Systemic) / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to the extended-release formulation of cysteamine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may diminish the therapeutic effect of Cysteamine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increases in WBC cystine concentration (ie, therapeutic failure of cysteamine) when the extended-release cysteamine product is combined with proton pump inhibitors. Administration of extended-release cysteamine with 240 mL of orange juice may reduce the magnitude of this interaction.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the extended-release cysteamine prescribing information, when a single dose of extended-release cysteamine (600 mg) was administered with 240 mL of orange juice after administration of 20 mg of omeprazole once daily for 5 days, the pharmacokinetic parameters of cysteamine were unchanged.<sup>1</sup> The effect of omeprazole on the pharmacokinetic parameters of extended-release cysteamine administered with water was not evaluated.<sup>1</sup><br><br>Prescribing information for extended-release cysteamine states that drugs that increase gastric pH (eg, proton pump inhibitors) may cause premature release of cysteamine from the extended-release product and could result in reduced efficacy (ie, increased WBC cystine concentration).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Procysbi (cysteamine) delayed-release capsules [prescribing information]. Novato, CA: Raptor Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9727":"<p><b>Title</b> Cysteamine (Systemic) / Histamine H2 Receptor Antagonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to the extended-release formulation of cysteamine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increases in WBC cystine concentration (ie, therapeutic failure of cysteamine) when the extended-release cysteamine product is combined with H2-receptor antagonists. Administration of extended-release cysteamine with 240 mL of orange juice may reduce the magnitude of this interaction.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the extended-release cysteamine prescribing information, when a single dose of extended-release cysteamine (600 mg) was administered with 240 mL of orange juice after administration of 20 mg of omeprazole once daily for 5 days, the pharmacokinetic parameters of cysteamine were unchanged.<sup>1</sup> The effect of omeprazole on the pharmacokinetic parameters of extended-release cysteamine administered with water was not evaluated.<sup>1</sup><br><br>Prescribing information for extended-release cysteamine states that drugs that increase gastric pH (eg, H2-receptor antagonists) may cause premature release of cysteamine from the extended-release product and could result in reduced efficacy (ie, increased WBC cystine concentration).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Procysbi (cysteamine) delayed-release capsules [prescribing information]. Novato, CA: Raptor Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9728":"<p><b>Title</b> Cysteamine (Systemic) / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to the extended-release formulation of cysteamine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may diminish the therapeutic effect of Cysteamine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increases in WBC cystine concentration (ie, therapeutic failure of cysteamine) when the extended-release cysteamine product is combined with antacids. Prescribing information suggests administration of extended-release cysteamine at least 1 hour before or 1 hour after medications that contain bicarbonate or carbonate.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the extended-release cysteamine prescribing information, when a single dose of extended-release cysteamine (600 mg) was administered with 240 mL of orange juice after administration of 20 mg of omeprazole once daily for 5 days, the pharmacokinetic parameters of cysteamine were unchanged.<sup>1</sup> The effect of omeprazole on the pharmacokinetic parameters of extended-release cysteamine administered with water was not evaluated.<sup>1</sup><br><br>Prescribing information for extended-release cysteamine states that drugs that increase gastric pH (eg, antacids) may cause premature release of cysteamine from the extended-release product and could result in reduced efficacy (ie, increased WBC cystine concentration).<sup>1</sup> Administration of extended-release cysteamine at least 1 hour before or 1 hour after medications that contain bicarbonate or carbonate is recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Procysbi (cysteamine) delayed-release capsules [prescribing information]. Novato, CA: Raptor Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9729":"<p><b>Title</b> Cysteamine (Systemic) / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction only applies to the extended-release form of cysteamine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Cysteamine (Systemic). Alcohol (Ethyl) may diminish the therapeutic effect of Cysteamine (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid alcohol consumption while taking extended-release cysteamine.</p> \n<p><b>Discussion</b> According to the prescribing information, consumption of alcohol with extended-release cysteamine may increase the rate of cysteamine release and lead to reduced efficacy and/or increased toxicity.<sup>1</sup> Therefore, consumption of alcoholic beverages during treatment with extended-release cysteamine should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Procysbi (cysteamine) delayed-release capsules [prescribing information]. Novato, CA: Raptor Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9730":"<p><b>Title</b> ALPRAZolam / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of ALPRAZolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased alprazolam effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir.</p> \n<p><b>Discussion</b> In a clinical study described in prescribing information, the alprazolam (0.5 mg single dose) AUC and maximum serum concentration increased 34% and 9%, respectively, when administered to 12 healthy volunteers taking the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product.<sup>1,2</sup><br><br>The mechanism of this interaction has not been fully investigated, but inhibition of CYP3A4, an enzyme responsible for alprazolam metabolism, by ombitasvir/paritaprevir/ritonavir/dasabuvir likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9731":"<p><b>Title</b> ALPRAZolam / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of ALPRAZolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased alprazolam effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir/dasabuvir.</p> \n<p><b>Discussion</b> In a clinical study described in prescribing information, the alprazolam (0.5 mg single dose) AUC and maximum serum concentration increased 34% and 9%, respectively, when administered to 12 healthy volunteers taking the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product.<sup>1,2</sup><br><br>The mechanism of this interaction has not been fully investigated, but inhibition of CYP3A4, an enzyme responsible for alprazolam metabolism, by ombitasvir/paritaprevir/ritonavir/dasabuvir likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9732":"<p><b>Title</b> Amiodarone / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations for management of this interaction differ between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased amiodarone effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir.</p> \n<p><b>Discussion</b> US prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir/dasabuvir and ombitasvir/paritaprevir/ritonavir) recommends additional monitoring for evidence of increased amiodarone effects/toxicities and monitoring of amiodarone serum concentrations (if available) when these agents are combined.<sup>1,2</sup> Canadian labeling for the antihepaciviral products recommends avoiding concomitant use with amiodarone.<sup>3,4</sup> <br><br>The suspected primary mechanism of interaction between these agents is inhibition of CYP3A4-mediated amiodarone metabolism by antihepaciviral combination products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9733":"<p><b>Title</b> Amiodarone / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations for management of this interaction differ between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased amiodarone effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir/dasabuvir. Canadian labeling recommends avoiding this combination.</p> \n<p><b>Discussion</b> US prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir/dasabuvir and ombitasvir/paritaprevir/ritonavir) recommends additional monitoring for evidence of increased amiodarone effects/toxicities and monitoring of amiodarone serum concentrations (if available) when these agents are combined.<sup>1,2</sup> Canadian labeling for the antihepaciviral products recommends avoiding concomitant use with amiodarone.<sup>3,4</sup> <br><br>The suspected primary mechanism of interaction between these agents is inhibition of CYP3A4-mediated amiodarone metabolism by antihepaciviral combination products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9734":"<p><b>Title</b> Buprenorphine / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Buprenorphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased buprenorphine effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 11 healthy subjects, coadministration of ombitasvir/paritaprevir/ritonavir with buprenorphine (4 to 24 mg daily) increased the buprenorphine dose normalized AUC and Cmax 1.5-fold and 1.2-fold, respectively.<sup>1</sup> In a clinical study of 19 patients taking buprenorphine, use of ombitasvir/paritaprevir/ritonavir/dasabuvir for 12 weeks achieved a sustained virologic response in over 97% of patients and no dose adjustments to buprenorphine therapy were required.<sup>2</sup><br><br>Prescribing information states that patients should be monitored for increased buprenorphine effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir, but no dose adjustment is required.<sup>1</sup><br><br>The primary mechanism of this interaction is likely inhibition of CYP3A4-mediated buprenorphine metabolism by ombitasvir/paritaprevir/ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. <i>J Heptaol</i>. 2015;63(2):364-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25839406\">[PubMed 25839406]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9735":"<p><b>Title</b> Buprenorphine / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Buprenorphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased buprenorphine effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir/dasabuvir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir with buprenorphine (4 to 24 mg daily) increased the buprenorphine dose normalized AUC and maximum serum concentration (Cmax) 2.1-fold and 2.2-fold, respectively, in 10 healthy subjects.<sup>1</sup> In a clinical study of 19 patients taking buprenorphine, use of ombitasvir/paritaprevir/ritonavir/dasabuvir for 12 weeks achieved a sustained virologic response in over 97% of patients and no dose adjustments to buprenorphine therapy were required.<sup>2</sup><br><br>Prescribing information states that patients should be monitored for increased buprenorphine effects/toxicities if combined with ombitasvir/paritaprevir/ritonavir/dasabuvir, but no dose adjustment is required.<sup>1</sup><br><br>The primary mechanism of this interaction is likely inhibition of CYP3A4-mediated buprenorphine metabolism by ombitasvir/paritaprevir/ritonavir/dasabuvir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. <i>J Heptaol</i>. 2015;63(2):364-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25839406\">[PubMed 25839406]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9738":"<p><b>Title</b> Methadone / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir does not appear to affect serum concentration of Methadone. <b>Severity</b> N/A <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 patients on stable methadone therapy, the coadministration of methadone (20 mg to 120 mg daily on days 1 to 25) with ombitasvir/paritaprevir/ritonavir/dasabuvir (on days 9 to 22) resulted in no change to the AUC or maximum serum concentration of R-methadone or S-methadone.<sup>1</sup> In a clinical study of 19 patients on methadone, use of ombitasvir/paritaprevir/ritonavir/dasabuvir for 12 weeks achieved a sustained virologic response in over 97% of patients, and no dose adjustments to methadone therapy were required.<sup>2</sup><br><br>Prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) states that no dose adjustments or increased clinical monitoring is needed when these products are combined with methadone.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. <i>J Hepatol</i>. 2015;63(1):20-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646891\">[PubMed 25646891]</a></p>\n<p>2. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. <i>J Heptaol</i>. 2015;63(2):364-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25839406\">[PubMed 25839406]</a></p>\n<p>3. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9739":"<p><b>Title</b> Methadone / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir does not appear to affect serum concentration of Methadone. <b>Severity</b> N/A <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 patients on stable methadone therapy, the coadministration of methadone (20 mg to 120 mg daily on days 1 to 25) with ombitasvir/paritaprevir/ritonavir/dasabuvir (on days 9 to 22) resulted in no change to the AUC or maximum serum concentration of R-methadone or S-methadone.<sup>1</sup> In a clinical study of 19 patients on methadone, use of ombitasvir/paritaprevir/ritonavir/dasabuvir for 12 weeks achieved a sustained virologic response in over 97% of patients, and no dose adjustments to methadone therapy were required.<sup>2</sup><br><br>Prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) states that no dose adjustments or increased clinical monitoring is needed when these products are combined with methadone.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. <i>J Hepatol</i>. 2015;63(1):20-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646891\">[PubMed 25646891]</a></p>\n<p>2. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. <i>J Heptaol</i>. 2015;63(2):364-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25839406\">[PubMed 25839406]</a></p>\n<p>3. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9740":"<p><b>Title</b> Escitalopram / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may decrease the serum concentration of Escitalopram. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In pharmacokinetic study of 10 healthy volunteers, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir (daily for 14 days) and escitalopram (10 mg single dose) decreased the escitalopram AUC 13% and had no effect on the escitalopram maximum serum concentration.<sup>1</sup> The S-demethyl citalopram metabolite AUC increased 36%.<sup>1</sup><br><br>Product labeling for antihepaciviral combination products states that no dose adjustment of escitalopram is required with combined with ombitasvir/paritaprevir/ritonavir/dasabuvir or ombitasvir/paritaprevir/ritonavir.<sup>2,3</sup><br><br>The mechanism of this potential interaction has not been investigated, but induction of CYP2C19-mediated escitalopram metabolism by the ritonavir component of the antihepaciviral combination products may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. <i>J Hepatol</i>. 2015;63(1):20-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646891\">[PubMed 25646891]</a></p>\n<p>2. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9741":"<p><b>Title</b> Escitalopram / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may decrease the serum concentration of Escitalopram. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In pharmacokinetic study of 10 healthy volunteers, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir (daily for 14 days) and escitalopram (10 mg single dose) decreased the escitalopram AUC 13% and had no effect on the escitalopram maximum serum concentration.<sup>1</sup> The S-demethyl citalopram metabolite AUC increased 36%.<sup>1</sup><br><br>Product labeling for antihepaciviral combination products states that no dose adjustment of escitalopram is required with combined with ombitasvir/paritaprevir/ritonavir/dasabuvir or ombitasvir/paritaprevir/ritonavir.<sup>2,3</sup><br><br>The mechanism of this potential interaction has not been investigated, but induction of CYP2C19-mediated escitalopram metabolism by the ritonavir component of the antihepaciviral combination products may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. <i>J Hepatol</i>. 2015;63(1):20-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646891\">[PubMed 25646891]</a></p>\n<p>2. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9742":"<p><b>Title</b> Ombitasvir, Paritaprevir, and Ritonavir / Mefloquine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mefloquine may decrease the serum concentration of Ombitasvir, Paritaprevir, and Ritonavir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Steady state AUC and maximum serum concentration of ritonavir (200 mg twice daily for 7 days) decreased 31% and 36%, respectively, in 12 healthy subjects when administered with the last dose of a 4-week course of mefloquine (250 mg/week, preceded by a 3-day course at the same dose).<sup>1</sup> An evaluation of the effects of mefloquine on a single dose of ritonavir failed to show any pharmacokinetic changes.<sup>1</sup> CYP3A4 effects and altered protein binding were mechanisms ruled out by the authors. Ritonavir is reported to be a P-glycoprotein substrate, and mefloquine a P-glycoprotein inhibitor. These characteristics would lead one to predict increased, not decreased, ritonavir concentrations. Therefore, a mechanism for this apparent interaction remains unclear.<br><br>Additional data from the same report demonstrates that ritonavir has little, if any, effect on mefloquine pharmacokinetics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2001;51(6):591-600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422019\">[PubMed 11422019]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9743":"<p><b>Title</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir / Mefloquine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mefloquine may decrease the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Steady state AUC and maximum serum concentration of ritonavir (200 mg twice daily for 7 days) decreased 31% and 36%, respectively, in 12 healthy subjects when administered with the last dose of a 4-week course of mefloquine (250 mg/week, preceded by a 3-day course at the same dose).<sup>1</sup> An evaluation of the effects of mefloquine on a single dose of ritonavir failed to show any pharmacokinetic changes.<sup>1</sup> CYP3A4 effects and altered protein binding were mechanisms ruled out by the authors. Ritonavir is reported to be a P-glycoprotein substrate, and mefloquine a P-glycoprotein inhibitor. These characteristics would lead one to predict increased, not decreased, ritonavir concentrations. Therefore, a mechanism for this apparent interaction remains unclear.<br><br>Additional data from the same report demonstrates that ritonavir has little, if any, effect on mefloquine pharmacokinetics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2001;51(6):591-600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422019\">[PubMed 11422019]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9744":"<p><b>Title</b> QuiNIDine / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased quinidine effects/toxicities and monitor quinidine serum concentrations if combined with ombitasvir/paritaprevir/ritonavir. Canadian labeling recommends avoiding this combination.</p> \n<p><b>Discussion</b> US prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir/dasabuvir and ombitasvir/paritaprevir/ritonavir) recommends additional monitoring for evidence of increased quinidine effects/toxicities and monitoring of quinidine serum concentrations (if available) when these agents are combined.<sup>1,2</sup> Canadian labeling for the antihepaciviral products recommends avoiding concomitant use with quinidine.<sup>3,4</sup> <br><br>The suspected primary mechanism of interaction between these agents is the inhibition of CYP3A4-mediated quinidine metabolism by antihepaciviral combination products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9745":"<p><b>Title</b> QuiNIDine / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased quinidine effects/toxicities and monitor quinidine serum concentrations if combined with ombitasvir/paritaprevir/ritonavir/dasabuvir. Canadian labeling recommends avoiding this combination.</p> \n<p><b>Discussion</b> US prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir/dasabuvir and ombitasvir/paritaprevir/ritonavir) recommends additional monitoring for evidence of increased quinidine effects/toxicities and monitoring of quinidine serum concentrations (if available) when these agents are combined.<sup>1,2</sup> Canadian labeling for the antihepaciviral products recommends avoiding concomitant use with quinidine.<sup>3,4</sup> <br><br>The suspected primary mechanism of interaction between these agents is the inhibition of CYP3A4-mediated quinidine metabolism by antihepaciviral combination products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9746":"<p><b>Title</b> Ombitasvir, Paritaprevir, and Ritonavir / Zolpidem</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Zolpidem may decrease the serum concentration of Ombitasvir, Paritaprevir, and Ritonavir. Specifically, the serum concentration of paritaprevir may be decreased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir (daily for 14 days) and zolpidem (5 mg single dose) had no effect on the zolpidem AUC or maximum serum concentration (Cmax), but did decrease the paritaprevir AUC and Cmax 32% and 37%, respectively.<sup>1</sup><br><br>Product labeling for antihepaciviral combination products states that no dose adjustment of zolpidem is required when combined with ombitasvir/paritaprevir/ritonavir/dasabuvir or ombitasvir/paritaprevir/ritonavir, and that the decreases in paritaprevir concentrations are unlikely to be clinically significant.<sup>2,3</sup><br><br>The mechanism(s) of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. <i>J Hepatol</i>. 2015;63(1):20-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646891\">[PubMed 25646891]</a></p>\n<p>2. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9747":"<p><b>Title</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir / Zolpidem</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Zolpidem may decrease the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. Specifically, the serum concentration of paritaprevir may be decreased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir (daily for 14 days) and zolpidem (5 mg single dose) had no effect on the zolpidem AUC or maximum serum concentration (Cmax), but did decrease the paritaprevir AUC and Cmax 32% and 37%, respectively.<sup>1</sup><br><br>Product labeling for antihepaciviral combination products states that no dose adjustment of zolpidem is required when combined with ombitasvir/paritaprevir/ritonavir/dasabuvir or ombitasvir/paritaprevir/ritonavir, and that the decreases in paritaprevir concentrations are unlikely to be clinically significant.<sup>2,3</sup><br><br>The mechanism(s) of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. <i>J Hepatol</i>. 2015;63(1):20-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646891\">[PubMed 25646891]</a></p>\n<p>2. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9748":"<p><b>Title</b> Levosulpiride / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of anticholinergic medications with levosulpiride should be avoided.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The levosulpiride labeling cautions that concurrent use of anticholinergics should be avoided due to the potential for such medications to decrease levosulpiride effectiveness.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Levopride (levosulpiride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501757. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9749":"<p><b>Title</b> Cardiac Glycosides / Levosulpiride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Levosulpiride may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, levosulpiride may diminish symptoms of cardiac glycoside-related toxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor response to cardiac glycosides more closely with concurrent levosulpiride, and be aware that levosulpiride may diminish some of the common symptoms of cardiac glycoside toxicity such as nausea, vomiting, or anorexia.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> The levosulpiride labeling cautions that levosulpiride may diminish some usual symptoms of cardiac glycoside toxicity, such as nausea, vomiting, or anorexia, potentially delaying the identification of toxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Levopride (levosulpiride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501757. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9750":"<p><b>Title</b> Levosulpiride / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Levosulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of levosulpiride with alcohol.</p> \n<p><b>Discussion</b> The levosulpiride labeling cautions that concurrent use of alcohol with levosulpiride.<sup>1</sup> Although specific details regarding the potential interaction are not described, the warning suggests that the combination may result in an increased risk for adverse effects. The levosulpiride labeling does caution that patients should avoid driving or operating heavy machinery, and adverse effects including drowsiness, dizziness, and stumbling are listed, all of which supports that alcohol may intensify such adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Levopride (levosulpiride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501757. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9751":"<p><b>Title</b> Flibanserin / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the hypotensive effect of Flibanserin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The consumption of alcohol during treatment with flibanserin is contraindicated. Concomitant use significantly increases the risk of hypotension and syncope. Before prescribing flibanserin, prescribers should assess the likelihood of the patient abstaining from alcohol, and counsel patients about the importance of complete abstinence from alcohol.</p> \n<p><b>Discussion</b> In a dedicated alcohol interaction study (N = 25) described in the flibanserin prescribing information, hypotension or syncope requiring intervention (ammonia salts and/or placement in supine or Trendelenberg position) occurred in 17% of healthy participants who received flibanserin 100 mg with 0.4 g/kg of alcohol.<sup>1</sup> Systolic blood pressure reductions ranged from 28 to 54 mm Hg.<sup>1</sup> Additionally, orthostatic hypotension occurred in 25% of the participants when they received flibanserin 100 mg with 0.8 g/kg of alcohol.<sup>1</sup> There were no events requiring therapeutic intervention when flibanserin or alcohol was administered alone.<sup>1</sup><br><br>During premarketing use of flibanserin one death occurred in a 54 year-old woman 14 days after starting flibanserin 100 mg daily. The patient had a history of baseline alcohol consumption of 1 to 3 drinks daily and her blood alcohol concentration at autopsy was 0.289 g/dL. The relationship between this patient’s death and use of flibanserin is unknown, but a causal link cannot be excluded.<sup>1</sup><br><br>The mechanism of this interaction is unknown, but does not appear to be a pharmacokinetic interaction, as pharmacokinetic parameters of flibanserin were unchanged when administered with alcohol.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9752":"<p><b>Title</b> Flibanserin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of flibanserin with strong or moderate inhibitors of CYP3A4 is contraindicated and should be avoided. If initiating flibanserin following CYP3A4 inhibitor use, start 2 weeks after the last dose of the CYP3A4 inhibitor. If initiating a CYP3A4 inhibitor following flibanserin use, start the CYP3A4 inhibitor 2 days after the last dose of flibanserin.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies described in the flibanserin prescribing information evaluated the use of flibanserin with strong or moderate CYP3A4 inhibitors. Ketoconazole (400 mg daily for 5 days) increased the flibanserin (50 mg single dose) AUC and maximum serum concentration (Cmax) 4.5-fold and 1.8-fold, respectively, in 24 healthy volunteers.<sup>1</sup> Itraconazole (400 mg single dose, then 200 mg daily for 4 days) increased the flibanserin (50 mg single dose) AUC and Cmax 2.6-fold and 1.7-fold, respectively, in 12 healthy volunteers.<sup>1</sup> Consumption of 240 mL of grapefruit juice increased the flibanserin (100 mg single dose) AUC and Cmax 1.4-fold and 1.1-fold, respectively, in 26 healthy subjects.<sup>1</sup> In another study of 15 healthy volunteers, fluconazole (400 mg single dose, then 200 mg daily for 5 days) increased the flibanserin (100 mg single dose) AUC and Cmax 7-fold and 2.2-fold, respectively.<sup>1</sup> Hypotension or syncope occurred in 3 patients (20%) and the study was terminated early.<sup>1</sup> <br><br>Prescribing information for flibanserin states that concomitant use of flibanserin with strong or moderate CYP3A4 inhibitors is contraindicated as concomitant use may increase flibanserin exposure and increase the risk for hypotension and syncope.<sup>1</sup> <br><br>The mechanism of this interaction is inhibition of CYP3A4, an enzyme primarily responsible for flibanserin metabolism, by CYP3A4 inhibitors. The magnitude of this interaction will likely be greater with drugs that inhibit multiple CYP enzymes involved in flibanserin metabolism (ie, fluconazole) compared with those that are exclusively CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9753":"<p><b>Title</b> Flibanserin / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of flibanserin with strong or moderate inhibitors of CYP3A4 is contraindicated and should be avoided. If initiating flibanserin following CYP3A4 inhibitor use, start 2 weeks after the last dose of the CYP3A4 inhibitor. If initiating a CYP3A4 inhibitor following flibanserin use, start the CYP3A4 inhibitor 2 days after the last dose of flibanserin.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies described in the flibanserin prescribing information evaluated the use of flibanserin with strong or moderate CYP3A4 inhibitors. Ketoconazole (400 mg daily for 5 days) increased the flibanserin (50 mg single dose) AUC and maximum serum concentration (Cmax) 4.5-fold and 1.8-fold, respectively, in 24 healthy volunteers.<sup>1</sup> Itraconazole (400 mg single dose, then 200 mg daily for 4 days) increased the flibanserin (50 mg single dose) AUC and Cmax 2.6-fold and 1.7-fold, respectively, in 12 healthy volunteers.<sup>1</sup> Consumption of 240 mL of grapefruit juice increased the flibanserin (100 mg single dose) AUC and Cmax 1.4-fold and 1.1-fold, respectively, in 26 healthy subjects.<sup>1</sup> In another study of 15 healthy volunteers, fluconazole (400 mg single dose, then 200 mg daily for 5 days) increased the flibanserin (100 mg single dose) AUC and Cmax 7-fold and 2.2-fold, respectively.<sup>1</sup> Hypotension or syncope occurred in 3 patients (20%) and the study was terminated early.<sup>1</sup> <br><br>Prescribing information for flibanserin states that concomitant use of flibanserin with strong or moderate CYP3A4 inhibitors is contraindicated as concomitant use may increase flibanserin exposure and increase the risk for hypotension and syncope.<sup>1</sup> <br><br>The mechanism of this interaction is inhibition of CYP3A4, an enzyme primarily responsible for flibanserin metabolism, by CYP3A4 inhibitors. The magnitude of this interaction will likely be greater with drugs that inhibit multiple CYP enzymes involved in flibanserin metabolism (ie, fluconazole) compared with those that are exclusively CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9754":"<p><b>Title</b> Flibanserin / CYP3A4 Inhibitors (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased flibanserin toxicities (eg, hypotension, syncope) if combined with weak CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Weak) Interacting Members</b> ALPRAZolam, Amiodarone, AmLODIPine, AtorvaSTATin, Bicalutamide, Bitter Orange, Cilostazol, Cimetidine, Ciprofloxacin (Systemic), Clotrimazole (Oral), CycloSPORINE (Systemic), Danazol, Dasatinib, Delavirdine, Everolimus, FluvoxaMINE, Fosaprepitant, Glecaprevir and Pibrentasvir, Goldenseal, Grazoprevir, Iloperidone, Isoniazid, Ivacaftor, Lapatinib, Lomitapide, Lurasidone, NiCARdipine, Palbociclib, PAZOPanib, Peppermint, Piperaquine, Propiverine, Propofol, QuiNIDine, Quinupristin, Ranolazine, Resveratrol, Roxithromycin, Ticagrelor, Tofisopam</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies described in the flibanserin prescribing information evaluated the use of flibanserin with strong or moderate CYP3A4 inhibitors. Ketoconazole (400 mg daily for 5 days) increased the flibanserin (50 mg single dose) AUC and maximum serum concentration (Cmax) 4.5-fold and 1.8-fold, respectively, in 24 healthy volunteers.<sup>1</sup> Itraconazole (400 mg single dose, then 200 mg daily for 4 days) increased the flibanserin (50 mg single dose) AUC and Cmax 2.6-fold and 1.7-fold, respectively, in 12 healthy volunteers.<sup>1</sup> Consumption of 240 mL of grapefruit juice increased the flibanserin (100 mg single dose) AUC and Cmax 1.4-fold and 1.1-fold, respectively, in 26 healthy subjects.<sup>1</sup> In another study of 15 healthy volunteers, fluconazole (400 mg single dose, then 200 mg daily for 5 days) increased the flibanserin (100 mg single dose) AUC and Cmax 7-fold and 2.2-fold, respectively.<sup>1</sup> Hypotension or syncope occurred in 3 patients (20%) and the study was terminated early.<sup>1</sup><br><br>Prescribing information for flibanserin states that concomitant use of flibanserin with even weak CYP3A4 inhibitors (particularly if multiple weak inhibitors are used) may increase flibanserin exposure and increase the risk for syncope and hypotension.<sup>1</sup> Patients should be informed of this risk if these agents are combined and should be monitored closely for these adverse effects.<sup>1</sup><br><br>The mechanism of this interaction is inhibition of CYP3A4, an enzyme primarily responsible for flibanserin metabolism, by CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9756":"<p><b>Title</b> Flibanserin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of flibanserin and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the flibanserin prescribing information, the flibanserin (100 mg single dose) AUC decreased 95% when given after a 7-day course of the strong CYP3A4 inducer rifampin (600 mg daily) in 24 healthy volunteers.<sup>1</sup><br><br>The flibanserin prescribing information states that concomitant use of flibanserin and CYP3A4 inducers may substantially reduce flibanserin exposure and effects and use of flibanserin with CYP3A4 inducers is not recommended.<sup>1</sup><br><br>The mechanism of this interaction is induction of CYP3A4, the enzyme primarily responsible for flibanserin metabolism, by rifampin (or other CYP3A4 inducers).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9757":"<p><b>Title</b> Digoxin / Flibanserin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Flibanserin may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased digoxin serum concentrations and effects if combined with flibanserin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the flibanserin prescribing information, flibanserin (100 mg daily for 5 days) increased the digoxin (0.5 mg single dose) AUC and maximum serum concentration 2-fold and 1.5-fold, respectively, in 24 healthy volunteers.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but flibanserin inhibition of P-glycoprotein, a transporter involved in digoxin disposition, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9758":"<p><b>Title</b> Flibanserin / Estrogen Derivatives (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives (Contraceptive) may increase the serum concentration of Flibanserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased flibanserin toxicities (eg, hypotension, syncope, dizziness, somnolence, fatigue) if combined with estrogen-containing hormonal contraceptives.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Flibanserin prescribing information states that in meta-analysis of phase 1 study data, 17 hormonal contraceptive (HC) users had flibanserin AUC and maximum serum concentrations that were 1.4-fold and 1.3-fold higher, respectively, when compared with 91 participants who were not taking HCs.<sup>1</sup> Additionally, in 4 clinical trials, 1,466 patients (43%) reported concomitant use of HC at study enrollment. Although these trials were not prospectively designed to assess an interaction between flibanserin and HC, flibanserin-treated patients who reported HC use had a greater incidence of dizziness (13.4% vs 9.9%), somnolence (12.3% vs 10.6%), and fatigue (11.4% vs 7.5%) compared with flibanserin-treated patients who did not report HC use.<sup>1</sup> There were no meaningful differences in the incidence of these adverse reactions in placebo-treated patients who reported or did not report HC use.<sup>1</sup><br><br>Flibanserin prescribing information states that concomitant use of flibanserin and a HC may result in increased flibanserin exposure and the risk for adverse events. Patients should be informed of this risk and monitored closely for adverse effects.<sup>1</sup><br><br>The mechanism of this interaction has not been investigated. Flibanserin prescribing information states that HC inhibition of CYP3A4, an enzyme responsible for flibanserin metabolism, is the likely mechanism;<sup>1</sup> however, numerous studies suggest that HCs have little to no effect on CYP3A4.<sup>2,3,4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p>2. Winkler J, Goldammer M, Ludwig M, Rohde B, Zurth C. Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. [published online July 6, 2014]. <i>Eur J Drug Metab Pharmacokinet</i>. doi:10.1007/s13318-014-0215-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24997757\">[PubMed 24997757]</a></p>\n<p>3. Edelman A, Munar M, Elman MR, Koop D, Cherala G. Effect of the ethinyl estradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. <i>Br J Clin Pharmacol</i>. 2012;74(3):510-514. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22299599\">[PubMed 22299599]</a></p>\n<p>4. Chang SY, Chen C, Yang Z, Rodrigues AD. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. <i>Drug Metab Dispos</i>. 2009;37(8):1667-1675. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19454483\">[PubMed 19454483]</a></p>\n<p>5. Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinyl estradiol and gestodene on CYP3A4 activity as measured by midazolam 1-hydroxylation. <i>Br J Clin Pharmacol</i>. 2000;50(4):333-337. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11012556\">[PubMed 11012556]</a></p>\n<p>6. Balogh A, Gessinger S, Svarovsky U, et al. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans? <i>Eur J Clin Pharmacol</i>. 1998;54(9-10):729-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9923576\">[PubMed 9923576]</a></p>\n<p>7. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. <i>Clin Pharmacol Ther</i>. 1984;36(5):683-690. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6149030\">[PubMed 6149030]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9759":"<p><b>Title</b> Flibanserin / Progestins (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Progestins (Contraceptive) may increase the serum concentration of Flibanserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased flibanserin toxicities (eg, hypotension, syncope, dizziness, somnolence, fatigue) if combined with progestin-containing hormonal contraceptives.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Flibanserin prescribing information states that in meta-analysis of phase 1 study data, 17 hormonal contraceptive (HC) users had flibanserin AUC and maximum serum concentrations that were 1.4-fold and 1.3-fold higher, respectively, when compared with 91 participants who were not taking HCs.<sup>1</sup> Additionally, in 4 clinical trials, 1,466 patients (43%) reported concomitant use of HC at study enrollment. Although these trials were not prospectively designed to assess an interaction between flibanserin and HC, flibanserin-treated patients who reported HC use had a greater incidence of dizziness (13.4% vs 9.9%), somnolence (12.3% vs 10.6%), and fatigue (11.4% vs 7.5%) compared with flibanserin-treated patients who did not report HC use.<sup>1</sup> There were no meaningful differences in the incidence of these adverse reactions in placebo-treated patients who reported or did not report HC use.<sup>1</sup><br><br>Flibanserin prescribing information states that concomitant use of flibanserin and a HC may result in increased flibanserin exposure and the risk for adverse events. Patients should be informed of this risk and monitored closely for adverse effects.<sup>1</sup><br><br>The mechanism of this interaction has not been investigated. Flibanserin prescribing information states that HC inhibition of CYP3A4, an enzyme responsible for flibanserin metabolism, is the likely mechanism;<sup>1</sup> however, numerous studies suggest that HCs have little to no effect on CYP3A4.<sup>2,3,4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p>2. Winkler J, Goldammer M, Ludwig M, Rohde B, Zurth C. Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. [published online July 6, 2014]. <i>Eur J Drug Metab Pharmacokinet</i>. Doi:10.1007/s13318-014-0215-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24997757\">[PubMed 24997757]</a></p>\n<p>3. Edelman A, Munar M, Elman MR, Koop D, Cherala G. Effect of the ethinyl estradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. <i>Br J Clin Pharmacol</i>. 2012;74(3):510-514. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22299599\">[PubMed 22299599]</a></p>\n<p>4. Chang SY, Chen C, Yang Z, Rodrigues AD. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. <i>Drug Metab Dispos</i>. 2009;37(8):1667-1675. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19454483\">[PubMed 19454483]</a></p>\n<p>5. Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinyl estradiol and gestodene on CYP3A4 activity as measured by midazolam 1-hydroxylation. <i>Br J Clin Pharmacol</i>. 2000;50(4):333-337. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11012556\">[PubMed 11012556]</a></p>\n<p>6. Balogh A, Gessinger S, Svarovsky U, et al. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans? <i>Eur J Clin Pharmacol</i>. 1998;54(9-10):729-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9923576\">[PubMed 9923576]</a></p>\n<p>7. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. <i>Clin Pharmacol Ther</i>. 1984;36(5):683-690. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6149030\">[PubMed 6149030]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9760":"<p><b>Title</b> Levosulpiride / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Loop Diuretics may enhance the adverse/toxic effect of Levosulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Do not combine levosulpiride with drugs that can cause electrolyte abnormalities such as loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> The levosulpiride labeling cautions not to combine levosulpiride with drugs that can cause electrolyte abnormalities.<sup>1</sup> Although neither specific drugs nor details regarding the potential interaction are described, loop diuretics have strong associations with a risk for hypokalemia, hypomagnesemia, and hypocalcemia. The reason for the concern is likely the potential for levosulpiride to prolong the QT interval and the possible risk for precipitation of dangerous arrhythmias, and electrolyte abormalities such as hypokalemia and hypomagnesemia likely increase such risks.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Levopride (levosulpiride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501757. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9761":"<p><b>Title</b> Levosulpiride / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Levosulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Do not combine levosulpiride with drugs that can cause electrolyte abnormalities such as thiazide diuretics.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> The levosulpiride labeling cautions not to combine levosulpiride with drugs that can cause electrolyte abnormalities.<sup>1</sup> Although neither specific drugs nor details regarding the potential interaction are described, thiazide diuretics have strong associations with a risk for hypokalemia, hypomagnesemia, and hypercalcemia. The reason for the concern is likely the potential for levosulpiride to prolong the QT interval and the possible risk for precipitation of dangerous arrhythmias, and electrolyte abormalities such as hypokalemia and hypomagnesemia likely increase such risks.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Levopride (levosulpiride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501757. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9762":"<p><b>Title</b> Flibanserin / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of flibanserin and moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the flibanserin prescribing information, the flibanserin (100 mg single dose) AUC decreased 95% when given after a 7-day course of the strong CYP3A4 inducer rifampin (600 mg daily) in 24 healthy volunteers.<sup>1</sup> Additionally, steady state etravirine (a moderate CYP3A4 inducer) decreased flibanserin exposures by approximately 21%.<sup>1</sup><br><br>The flibanserin prescribing information states that concomitant use of flibanserin and CYP3A4 inducers may substantially reduce flibanserin exposure and effects and use of flibanserin with CYP3A4 inducers is not recommended.<sup>1</sup><br><br>The mechanism of this interaction is induction of CYP3A4, the enzyme primarily responsible for flibanserin metabolism, by rifampin, etravirine, or other CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9763":"<p><b>Title</b> Levosulpiride / Benzamide Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of levosulpiride with other benzamide derivatives, and monitor patients closely for evidence of extrapyramidal symptoms or other adverse effects.</p>\n<div>\n <p><b>Benzamide Derivatives Interacting Members</b> Amisulpride, Bromopride, Cisapride, Domperidone, Levosulpiride, Metoclopramide, Procarbazine, Prucalopride, Sulpiride, Trimethobenzamide</p>\n</div> \n<p><b>Discussion</b> The levosulpiride labeling cautions that concurrent use of levosulpiride with other benzamide derivatives may increase the risk for extrapyramidal symptoms or other adverse effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Levopride (levosulpiride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199501757. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9764":"<p><b>Title</b> Simvastatin / Flibanserin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Flibanserin may increase the serum concentration of Simvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the flibanserin prescribing information, flibanserin (50 mg twice daily for 4 days) increased the simvastatin (40 mg once daily) AUC and maximum serum concentration (Cmax) 1.3-fold and 1.2-fold, respectively, in 12 healthy volunteers.<sup>1</sup> The simvastatin acid AUC and Cmax increased 1.5-fold and 1.4-fold, respectively.<sup>1</sup> <br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Addyi (flibanserin) [prescribing information]. Raleigh, NC: Sprout Pharmaceuticals Inc; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9765":"<p><b>Title</b> CYP2C8 Substrates (High Risk with Inhibitors or Inducers) / Lumacaftor</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lumacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to any CYP2C8 substrates closely when used with lumacaftor. Drug effects may be increased or decreased.</p>\n<div>\n <p><b>CYP2C8 Substrates (High Risk with Inhibitors or Inducers) Interacting Members</b> Amiodarone, Amodiaquine, Dabrafenib, Dasabuvir, Enzalutamide, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Pioglitazone, Repaglinide, Rosiglitazone, Selexipag, Velpatasvir</p>\n</div> \n<p><b>Discussion</b> The prescribing information for lumacaftor/ivacaftor cautions that in vitro studies showed that lumacaftor could act as an inducer and/or inhibitor of CYP2C8.<sup>1</sup> As a result, lumacaftor may alter concentrations and effects of CYP2C8 substrates through induction and/or inhibition of CYP2C8-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orkambi (lumacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9766":"<p><b>Title</b> BCRP/ABCG2 Substrates / Eltrombopag</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Eltrombopag may increase the serum concentration of BCRP/ABCG2 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient closely for adverse effects related to any BCRP (also known as ABCG2) substrate when using these agents together with eltrombopag. The eltrombopag prescribing information cautions that consideration of a preventive dose reduction may be warranted.</p>\n<div>\n <p><b>BCRP/ABCG2 Substrates Interacting Members</b> Glecaprevir and Pibrentasvir, PAZOPanib, Rosuvastatin, SulfaSALAzine, Topotecan</p>\n</div> \n<p><b>Discussion</b> The AUC and maximum plasma concentration of the BCRP substrate rosuvastatin were increased an average of 55% and 103%, respectively, following administration of rosuvastatin (10 mg single dose) together with eltrombopag (75 mg daily for 5 days) in a study of 39 healthy volunteers.<sup>1,2</sup><br><br>The suspected mechanism of this interaction is inhibition of both the BCRP and OATP1B1 (also known as SLCO1B1) transporters that participate in the distribution and elimination of rosuvastatin.<sup>1,2,3</sup> In vitro data and a physiologically based pharmacokinetic model predicted that BCRP inhibition by eltrombopag is likely the primary mechanism for this reported interaction.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015.</p>\n<p>2. Allred AJ, Bowen CJ, Park JW, et al. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2011;72(2):321-329. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21434975\">[PubMed 21434975]</a></p>\n<p>3. Takeuchi K, Sugiura T, Matsubara K, et al. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. <i>Drug Metab Dispos</i>. 2014;42(4):726-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24440960\">[PubMed 24440960]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9767":"<p><b>Title</b> Eltrombopag / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lopinavir may decrease the serum concentration of Eltrombopag. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The eltrombopag AUC was an average of 17% lower with concurrent lopinavir/ritonavir in a study of 40 healthy volunteers who received a single dose of eltrombopag 100 mg together with lopinavir/ritonavir 400 mg/100 mg twice daily.<sup>1</sup><br><br>The precise mechanism of this apparent interaction is uncertain, but it may involve lopinavir/ritonavir induction of the glucuronidation of eltrombopag, as lopinavir/ritonavir is described as being capable of inducing glucuronidation and eltrombopag is subject to glucuronidation via UGT1A1 and UGT1A3.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015.</p>\n<p>2. Kaletra (lopinavir and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9768":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Tianeptine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tianeptine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of tianeptine and monoamine oxidase inhibitors (MAOIs). If switching from an MAOI to tianeptine, discontinue the MAOI 2 weeks prior to starting tianeptine. If switching from tianeptine to an MAOI, discontinue tianeptine at least 24 hours prior to starting the MAOI.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Phenelzine, Procarbazine, Syrian Rue, Tedizolid, Tranylcypromine<br><b>Exceptions</b> Moclobemide, Rasagiline, Safinamide, Selegiline</p>\n</div> \n<p><b>Discussion</b> Product labeling for tianeptine states that concomitant use of tianeptine and non-selective monoamine oxidase inhibitors (MAOIs) should be avoided due to the risk for cardiovascular collapse, hypertension, hyperthermia, convulsion, or death.<sup>1</sup> <br><br>The mechanism of this interaction is unknown. Although the mechanism of action of tianeptine has not been fully characterized, it does not inhibit MAO and is thought to either reduce or have neglible effects on serotonin and norepinephrine levels.<sup>2,3</sup> This would predict a much lower risk when combined with MAOIs compared with other antidepressants. One case report describes a 59-year-old female with refractory depression who used tianeptine combined with tranylcypromine for over 1 year and did not experience any adverse events with the combination.<sup>4</sup> Despite this pharmacology, due to the severity of this potential adverse reaction, product labeling recommends avoiding this combination.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stablon (tianeptine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199700688. Accessed July 20, 2016.</p>\n<p>2. McEwen BS, Chattarji S, Diamond DM, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. <i>Mol Psychiatry</i>. 2010;15(3):237-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19704408\">[PubMed 19704408]</a></p>\n<p>3. Lechin F, van der Dijs B, Hernandez G, Orozco B, Rodriguez S, Baez S. Acute effects of tianeptine on circulating neurotransmitters and cardiovascular parameters. <i>Prog Neurospychopharmacol Biol Psychiatry</i>. 2006;30(2):214-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16303223\">[PubMed 16303223]</a></p>\n<p>4. Tobe EH. Tianeptine in combination with monoamine oxidase inhibitors for major depressive disorder [published online October 9, 2012]. <i>BMJ Case Rep</i>. Doi: 10.1136/bcr-2012-007044. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23048001\">[PubMed 23048001]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9769":"<p><b>Title</b> Tianeptine / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mianserin may diminish the therapeutic effect of Tianeptine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of tianeptine and mianserin.</p> \n<p><b>Discussion</b> Product labeling for tianeptine states that the concomitant use of tianeptine and mianserin should be avoided due to antagonism of drug effects seen in experimental models.<sup>1</sup><br><br>The mechanism of this interaction is unknown. No further details about this interaction are provided in the product labeling and no reports regarding this interaction have been published.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stablon (tianeptine) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199700688. Accessed July 20, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9770":"<p><b>Title</b> Tianeptine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Alcohol (Ethyl) may decrease the serum concentration of Tianeptine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, a single loading dose (1.5 mL/kg for women, 1.75 mL/kg for men) of alcohol (40% vodka diluted with orange juice) administered 1 hour prior to tianeptine (12.5 mg single oral dose) decreased both the tianeptine AUC and maximum serum concentration 29%.<sup>1</sup> <br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Salvadori C, Ward C, Defrance R, Hopkins R. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. <i>Fundam Clin Pharmacol</i>. 1990;4(1):115-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2341111\">[PubMed 2341111]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9771":"<p><b>Title</b> Ramosetron / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the constipating effect of Ramosetron. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving ramosetron in combination with an anticholinergic agent for an increased risk of constipation.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Ramosetron Korean product labeling states that its use in combination with anticholinergic agents may increase the risk of adverse effects including constipation.<sup>1</sup> This interaction is anticipated based on the independent constipating effects of ramosetron and anticholinergic agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Irribow (ramosetron) tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200905270. Accessed June 17, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9772":"<p><b>Title</b> Ramosetron / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Opioid Analgesics may enhance the constipating effect of Ramosetron. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving ramosetron in combination with an opioid analgesic for an increased risk of constipation.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> Ramosetron Korean product labeling states that its use in combination with opioid analgesics may increase the risk of adverse effects including constipation.<sup>1</sup> This interaction is anticipated based on the independent constipating effects of ramosetron and opioid analgesics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Irribow (ramosetron) tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200905270. Accessed June 17, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9774":"<p><b>Title</b> Lactulose / Glutamine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: This interaction is specific to the use of lactulose to treat hyperammonemia and/or hyperammonemic encephalopathy.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Glutamine may diminish the therapeutic effect of Lactulose. Specifically, glutamine may diminish the ammonia-lowering effects of lactulose. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to lactulose therapy closely, and consider alternatives to glutamine as clinically appropriate.</p> \n<p><b>Discussion</b> One use of lactulose is as treatment of hyperammonemic encephalopathy, as lactose works to decrease ammonia concentrations by a variety of mechanisms.<sup>1,2,3</sup> Glutamine administration may oppose these actions, as glutamine may both increase systemic ammonia concentrations as well as increase swelling and edema in the central nervous system.<sup>1,2</sup><br><br>There is no evidence that glutamine would oppose the laxative effects of lactulose.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rai R, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy. <i>J Clin Exp Hepatol</i>. 2015;5(Suppl 1):S29-S36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26041954\">[PubMed 26041954]</a></p>\n<p>2. Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. <i>Best Pract Res Clin Gastroenterol</i>. 2007;21(1):95-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17223499\">[PubMed 17223499]</a></p>\n<p>3. Enulose (lactulose) [prescribing information]. Morristown, NJ: Actavis Inc.; January 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9775":"<p><b>Title</b> Bosutinib / Star Fruit</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Star Fruit may increase the serum concentration of Bosutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The bosutinib Canadian product monograph recommends avoiding concurrent use of star fruit due to the potential for star fruit to inhibit the CYP3A4-mediated metabolism of bosutinib. While the U.S. prescribing information similarly cautions to avoid concurrent use with strong or moderate CYP3A4 inhibitors, it does not list star fruit as a specific example of such an inhibitor.</p> \n<p><b>Discussion</b> The bosutinib Canadian product monograph recommends avoiding concurrent use of star fruit due to the potential for star fruit to inhibit the CYP3A4-mediated metabolism of bosutinib, increasing bosutinib concentrations.<sup>1</sup> The U.S. prescribing information similarly cautions to avoid concurrent use with strong or moderate CYP3A4 inhibitors, but it does not list star fruit as a specific example of such an inhibitor.<sup>2</sup><br><br>The degree to which star fruit, which is described in the bosutinib monograph as a moderate CYP3A4 inhibitor, inhibits CYP3A4 is uncertain. Several in vitro studies demonstrate a potential for star fruit to inhibit CYP3A4,<sup>3,4,5</sup> but clinical evidence regarding the magnitude of any such inhibition is lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bosulif (bosutinib) [product monograph]. Kirkland, Quebec, Canada: Wyeth LLC; July 2015.</p>\n<p>2. Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; November 2014.</p>\n<p>3. Zhang JW, Liu Y, Cheng J, et al. Inhibition of human liver cytochrome P450 by star fruit juice. <i>J Pharm Pharm Sci</i>. 2007;10(4):496-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18261370\">[PubMed 18261370]</a></p>\n<p>4. Hidaka M, Okumura M, Ogikubo T, et al. Transient inhibition of cyp3a in rats by star fruit juice. <i>Drug Metab Dispos</i>. 2006;34(3):343-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16326816\">[PubMed 16326816]</a></p>\n<p>5. Hidaka M, Fujita K, Ogikubo T, et al. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. <i>Drug Metab Dispos</i>. 2004;32(6):581-583. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15155547\">[PubMed 15155547]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9776":"<p><b>Title</b> Bosutinib / Pomegranate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pomegranate may increase the serum concentration of Bosutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The bosutinib Canadian product monograph recommends avoiding concurrent use of pomegranate due to the potential for pomegranate to inhibit the CYP3A4-mediated metabolism of bosutinib. While the U.S. prescribing information similarly cautions to avoid concurrent use with strong or moderate CYP3A4 inhibitors, it does not list pomegranate as a specific example of such an inhibitor.</p> \n<p><b>Discussion</b> The bosutinib Canadian product monograph recommends avoiding concurrent use of pomegranate due to the potential for pomegranate to inhibit the CYP3A4-mediated metabolism of bosutinib, increasing bosutinib concentrations.<sup>1</sup> The U.S. prescribing information similarly cautions to avoid concurrent use with strong or moderate CYP3A4 inhibitors, but it does not list pomegranate as a specific example of such an inhibitor.<sup>2</sup><br><br>Although pomegranate is described in the bosutinib monograph as a moderate CYP3A4 inhibitor, available clinical evidence suggests it has little if any CYP3A4 inhibition in vivo. Administration of pomegranate juice 3 times daily (900 mL/day) for 3 days was associated with only a non-significant 29% increase in simvastatin AUC in a study of 16 healthy volunteers (versus more than a 9-fold increase in simvastatin AUC with grapefruit juice).<sup>3</sup> Similarly, ingestion of pomegranate juice (240 mL as single dose or 200 mL twice/day for 14 days) was associated with no significant change in midazolam pharmacokinetics (either IV or orally administered) in studies of 13 and 16 volunteers.<sup>4,5</sup> In total, these studies suggest pomegranate likely doesn't even qualify as a weak CYP3A4 inhibitor. These clinical studies are in contrast to several in vitro and animal studies that have reported significant CYP3A4 inhibition or interactions with CYP3A4 substrates.<sup>6,7,8,9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bosulif (bosutinib) [product monograph]. Kirkland, Quebec, Canada: Wyeth LLC; July 2015.</p>\n<p>2. Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; November 2014.</p>\n<p>3. Park SJ, Yeo CW, Shim EJ, et al. Pomegranate juice does not affect the disposition of simvastatin in healthy subjects. <i>Eur J Drug Metab Pharmacokinet</i>. 2015; Feb 27 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25720525\">[PubMed 25720525]</a></p>\n<p>4. Misaka S, Nakamura R, Uchida S, et al. Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. <i>Clin Ther</i>. 2011;33(2):246-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21497708\">[PubMed 21497708]</a></p>\n<p>5. Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. <i>J Clin Pharmacol</i>. 2007;47(3):286-294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17322140\">[PubMed 17322140]</a></p>\n<p>6. Voruganti S, Yamsani SK, Ravula SK, Gannu R, Yamsani MR. Effect of pomegranate juice on intestinal transport and pharmacokinetics of nitrendipine in rats. <i>Phytother Res</i>. 2012;26(8):1240-1245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22275232\">[PubMed 22275232]</a></p>\n<p>7. Voruganti S, Rapolu K, Tota S, Yamsani SK, Yamsani MR. Effect of pomegranate juice on the pharmacokinetics of nitrendipine in rabbits. <i>Eur J Drug Metab Pharmacokinet</i>. 2012;37(2):77-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22101410\">[PubMed 22101410]</a></p>\n<p>8. Shravan Kumar Y, Adukondalu D, Bhargavi Latha A, et al. Effect of pomegranate pretreatment on the oral bioavailability of buspirone in male albino rabbits. <i>Daru</i>. 2011;19(4):266-269. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22615667\">[PubMed 22615667]</a></p>\n<p>9. Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, Liu KH. Inhibitory effects of fruit juices on CYP3A activity. <i>Drug Metab Dispos</i>. 2006;34(4):521-523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16415112\">[PubMed 16415112]</a></p>\n<p>10. Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. <i>Drug Metab Dispos</i>. 2005;33(5):644-648. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15673597\">[PubMed 15673597]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9777":"<p><b>Title</b> Bosutinib / Bitter Orange</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bitter Orange may increase the serum concentration of Bosutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The bosutinib Canadian product monograph recommends avoiding concurrent use of Seville oranges (also known as Bitter oranges) due to the potential for the fruit to inhibit the CYP3A4-mediated metabolism of bosutinib. While the U.S. prescribing information similarly cautions to avoid concurrent use with strong or moderate CYP3A4 inhibitors, it does not list Seville oranges as a specific example of such an inhibitor.</p> \n<p><b>Discussion</b> The bosutinib Canadian product monograph recommends avoiding concurrent use of Seville oranges (aka Bitter oranges) due to the potential for the fruit to inhibit the CYP3A4-mediated metabolism of bosutinib, increasing bosutinib concentrations.<sup>1</sup> The U.S. prescribing information similarly cautions to avoid concurrent use with strong or moderate CYP3A4 inhibitors, but it does not list Seville oranges as a specific example of such an inhibitor.<sup>2</sup><br><br>The degree to which Seville oranges truly inhibit CYP3A4 in vivo is uncertain, though most evidence suggests it is at most a weak CYP3A4 inhibitor.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bosulif (bosutinib) [product monograph]. Kirkland, Quebec, Canada: Wyeth LLC; July 2015.</p>\n<p>2. Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; November 2014.</p>\n<p>3. Penzak SR, Acosta EP, Turner M, et al. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. <i>J Clin Pharmacol</i>. 2002;42(10):1165-1170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12362932\">[PubMed 12362932]</a></p>\n<p>4. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. <i>Life Sci</i>. 2002;71(10):1149-1160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12095536\">[PubMed 12095536]</a></p>\n<p>5. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. <i>Clin Pharmacol Ther</i>. 2001;69(1):14-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180034\">[PubMed 11180034]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9778":"<p><b>Title</b> Panobinostat / Star Fruit</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Star Fruit may increase the serum concentration of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients being treated with panobinostat should avoid ingestion of star fruit.</p> \n<p><b>Discussion</b> The panobinostat prescribing information recommends avoiding concurrent use of star fruit due to the potential for star fruit to inhibit the CYP3A-mediated metabolism of panobinostat, increasing panobinostat concentrations and the risk for toxicity.<sup>1</sup><br><br>The degree to which star fruit actually inhibits CYP3A4 is uncertain. Several in vitro studies demonstrate a potential for star fruit to inhibit CYP3A4,<sup>2,3,4</sup> but clinical evidence regarding the magnitude of any such inhibition is lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Farydak (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p>2. Zhang JW, Liu Y, Cheng J, et al. Inhibition of human liver cytochrome P450 by star fruit juice. <i>J Pharm Pharm Sci</i>. 2007;10(4):496-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18261370\">[PubMed 18261370]</a></p>\n<p>3. Hidaka M, Okumura M, Ogikubo T, et al. Transient inhibition of cyp3a in rats by star fruit juice. <i>Drug Metab Dispos</i>. 2006;34(3):343-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16326816\">[PubMed 16326816]</a></p>\n<p>4. Hidaka M, Fujita K, Ogikubo T, et al. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. <i>Drug Metab Dispos</i>. 2004;32(6):581-583. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15155547\">[PubMed 15155547]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9779":"<p><b>Title</b> Panobinostat / Pomegranate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pomegranate may increase the serum concentration of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients being treated with panobinostat should avoid ingestion of pomegranate.</p> \n<p><b>Discussion</b> The panobinostat prescribing information recommends avoiding concurrent use of pomegranate due to the potential for pomegranate to inhibit the CYP3A-mediated metabolism of panobinostat, increasing panobinostat concentrations and the risk for toxicity.<sup>1</sup><br><br>Although pomegranate is described in the panobinostat monograph as a CYP3A4 inhibitor, available clinical evidence suggests it has little if any CYP3A4 inhibition in vivo. Administration of pomegranate juice 3 times daily (900 mL/day) for 3 days was associated with only a non-significant 29% increase in simvastatin AUC in a study of 16 healthy volunteers (versus more than a 9-fold increase in simvastatin AUC with grapefruit juice).<sup>2</sup> Similarly, ingestion of pomegranate juice (240 mL as single dose or 200 mL twice/day for 14 days) was associated with no significant change in midazolam pharmacokinetics (either IV or orally administered) in studies of 13 and 16 volunteers.<sup>3,4</sup> In total, these studies suggest pomegranate likely doesn't even qualify as a weak CYP3A4 inhibitor. These clinical studies are in contrast to several in vitro and animal studies that have reported significant CYP3A4 inhibition or interactions with CYP3A4 substrates.<sup>5,6,7,8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Farydak (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p>2. Park SJ, Yeo CW, Shim EJ, et al. Pomegranate juice does not affect the disposition of simvastatin in healthy subjects. <i>Eur J Drug Metab Pharmacokinet</i>. 2015; Feb 27 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25720525\">[PubMed 25720525]</a></p>\n<p>3. Misaka S, Nakamura R, Uchida S, et al. Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. <i>Clin Ther</i>. 2011;33(2):246-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21497708\">[PubMed 21497708]</a></p>\n<p>4. Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. <i>J Clin Pharmacol</i>. 2007;47(3):286-294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17322140\">[PubMed 17322140]</a></p>\n<p>5. Voruganti S, Yamsani SK, Ravula SK, Gannu R, Yamsani MR. Effect of pomegranate juice on intestinal transport and pharmacokinetics of nitrendipine in rats. <i>Phytother Res</i>. 2012;26(8):1240-1245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22275232\">[PubMed 22275232]</a></p>\n<p>6. Voruganti S, Rapolu K, Tota S, Yamsani SK, Yamsani MR. Effect of pomegranate juice on the pharmacokinetics of nitrendipine in rabbits. <i>Eur J Drug Metab Pharmacokinet</i>. 2012;37(2):77-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22101410\">[PubMed 22101410]</a></p>\n<p>7. Shravan Kumar Y, Adukondalu D, Bhargavi Latha A, et al. Effect of pomegranate pretreatment on the oral bioavailability of buspirone in male albino rabbits. <i>Daru</i>. 2011;19(4):266-269. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22615667\">[PubMed 22615667]</a></p>\n<p>8. Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, Liu KH. Inhibitory effects of fruit juices on CYP3A activity. <i>Drug Metab Dispos</i>. 2006;34(4):521-523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16415112\">[PubMed 16415112]</a></p>\n<p>9. Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. <i>Drug Metab Dispos</i>. 2005;33(5):644-648. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15673597\">[PubMed 15673597]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9780":"<p><b>Title</b> Propacetamol / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: Published data suggest a potentially elevated risk of acetaminophen-associated hepatotoxicity in some alcoholic patients. Data supporting an elevated risk in other populations are sparse.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the hepatotoxic effect of Propacetamol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Hepatotoxicity of acetaminophen (a metabolite of propacetamol) has been reported in numerous published case reports involving alcoholic patients receiving acetaminophen doses typical of clinical practice (3-4 g/day or less). While the role of alcohol in these reactions is unclear, and the subpopulations at greatest risk of these effects have not been characterized, propacetamol should be used cautiously and with close monitoring for clinical or laboratory evidence of hepatotoxicity in alcoholic patients.</p> \n<p><b>Discussion</b> Acetaminophen US prescribing information warns that it should be used cautiously in alcoholic patients.<sup>1</sup> Numerous published case reports describe hepatotoxicity (with features including substantial transaminase concentration elevations, prolonged prothrombin time, and hepatic necrosis) in chronic alcoholic patients following acetaminophen use.<sup>2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21</sup> Several of these cases include patients who took acetaminophen within clinically recommended dose limits (3-4 g/day or less). However, despite the large number of published case reports, acetaminophen use in recently-abstinent alcoholic patients, or in patients who consume 1-3 drinks/day (including during acetaminophen coadministration), has not been associated with any consistent alterations in liver function tests (e.g., transaminase concentrations, prothrombin time) in several placebo-controlled randomized trials.<sup>22,23,24,25,26,27</sup><br><br>The exact mechanism of any interaction between acetaminophen and alcohol is not clear. Alcohol may theoretically act as both an inhibitor and an inducer (this latter effect expected only with longer-term use) of CYP2E1, an enzyme that can convert acetaminophen to the hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).<sup>1,28,29</sup> Glutathione depletion in alcoholism could also theoretically decrease conjugation of NAPQI and further increase its hepatotoxic risk. Both acetaminophen and alcohol can also exert hepatotoxic effects independent of other agents. Human data supporting the proposed mechanisms of interaction between these agents are sparse, however, and the available clinical data suggest at best a very poorly generalizable mechanism of interaction between these agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ofirmev</i> (acetaminophen) [prescribing information]. San Diego, CA: Cadence Pharmaceuticals, Inc; October 2013.</p>\n<p>2. Licht H, Seeff LB, Zimmerman HJ. Apparent potentiation of acetaminophen hepatotoxicity by alcohol. <i>Ann Intern Med</i>. 1980;92(4):511. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7362155\">[PubMed 7362155]</a></p>\n<p>3. Barker JD Jr, de Carle DJ, Anuras S. Chronic excessive acetaminophen use and liver damage. <i>Ann Intern Med</i>. 1977;87(3):299-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=900673\">[PubMed 900673]</a></p>\n<p>4. McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL. Potentiation of acetaminophen hepatotoxicity by alcohol. <i>JAMA</i>. 1980;244(3):251-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7382090\">[PubMed 7382090]</a></p>\n<p>5. Leist MH, Gluskin LE, Payne JA. Enhanced toxicity of acetaminophen in alcoholics: report of three cases. <i>J Clin Gastroenterol</i>. 1985;7(1):55-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3980965\">[PubMed 3980965]</a></p>\n<p>6. Goldfinger R, Ahmed KS, Pitchumoni CS, Weseley SA. Concomitant alcohol and drug abuse enhancing acetaminophen toxicity. Report of a case. <i>Am J Gastroenterol</i>. 1978;70(4):385-388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=727190\">[PubMed 727190]</a></p>\n<p>7. Kaysen GA, Pond SM, Roper MH, Menke DJ, Marrama MA. Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen. <i>Arch Intern Med</i>. 1985;145(11):2019-2023. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4062453\">[PubMed 4062453]</a></p>\n<p>8. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. <i>Ann Intern Med</i>. 1986;104(3):399-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3511825\">[PubMed 3511825]</a></p>\n<p>9. O'Dell JR, Zetterman RK, Burnett DA. Centrilobular hepatic fibrosis following acetaminophen-induced hepatic necrosis in an alcoholic. <i>JAMA</i>. 1986;255(19):2636-2637. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3701979\">[PubMed 3701979]</a></p>\n<p>10. Lesser PB, Vietti MM, Clark WD. Lethal enhancement of therapeutic doses of acetaminophen by alcohol. <i>Dig Dis Sci</i>. 1986;31(1):103-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3940815\">[PubMed 3940815]</a></p>\n<p>11. Kartsonis A, Reddy KR, Schiff ER. Alcohol, acetaminophen, and hepatic necrosis. <i>Ann Intern Med</i>. 1986;105(1):138-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3717790\">[PubMed 3717790]</a></p>\n<p>12. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. <i>Hepatology</i>. 1995;22(3):767-773. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7657281\">[PubMed 7657281]</a></p>\n<p>13. Gerber MA, Kaufmann H, Klion F, Alpert LI. Acetaminophen associated hepatic injury. Report of two cases showing unusual portal tract reactions. <i>Hum Pathol</i>. 1980;11(1):37-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7364436\">[PubMed 7364436]</a></p>\n<p>14. Johnson MW, Friedman PA, Mitch WE. Alcoholism, nonprescription drug and hepatotoxicity. The risk from unknown acetaminophen ingestion. <i>Am J Gastroenterol</i>. 1981;76(6):530-533. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7331985\">[PubMed 7331985]</a></p>\n<p>15. Black M, Cornell JF, Rabin L, Shachter N. Late presentation of acetaminophen hepatotoxicity. <i>Dig Dis Sci</i>. 1982;27(4):370-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7067588\">[PubMed 7067588]</a></p>\n<p>16. Erickson RA, Runyon BA. Acetaminophen hepatotoxicity associated with alcoholic pancreatitis. <i>Arch Intern Med</i>. 1984;144(7):1509, 1513. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6732414\">[PubMed 6732414]</a></p>\n<p>17. Himmelstein DU, Woolhandler SJ, Adler RD. Elevated SGOT/SGPT ratio in alcoholic patients with acetaminophen hepatotoxicity. <i>Am J Gastroenterol</i>. 1984;79(9):718-720. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6475903\">[PubMed 6475903]</a></p>\n<p>18. Fleckenstein JL. Nyquil and acute hepatic necrosis. <i>N Engl J Med</i>. 1985;313(1):48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4000227\">[PubMed 4000227]</a></p>\n<p>19. Denison H, Kaczynski J, Wallerstedt S. Paracetamol medication and alcohol abuse: a dangerous combination for the liver and the kidney. <i>Scand J Gastroenterol</i>. 1987;22(6):701-704. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3659833\">[PubMed 3659833]</a></p>\n<p>20. Floren CH, Thesleff P, Nilsson A. Severe liver damage caused by therapeutic doses of acetaminophen. <i>Acta Med Scand</i>. 1987;222(3):285-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3425381\">[PubMed 3425381]</a></p>\n<p>21. Davis AM, Helms CM, Mitros FA, Wong YW, LaBrecque DR. Severe hepatic damage after acetaminophen use in psittacosis. <i>Am J Med</i>. 1983;74(2):349-352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6824012\">[PubMed 6824012]</a></p>\n<p>22. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. <i>Aliment Pharmacol Ther</i>. 2007;26(2):283-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17593074\">[PubMed 17593074]</a></p>\n<p>23. Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. <i>Arch Intern Med</i>. 2001;161(18):2247-2252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11575982\">[PubMed 11575982]</a></p>\n<p>24. Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, Brands B. The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study. <i>Aliment Pharmacol Ther</i>. 2010;32(3):478-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20491750\">[PubMed 20491750]</a></p>\n<p>25. Kuffner EK, Green JL, Bogdan GM, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study. <i>BMC Med</i>. 2007;5:13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17537264\">[PubMed 17537264]</a></p>\n<p>26. Bartels S, Sivilotti M, Crosby D, Richard J. Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial. <i>Clin Toxicol (Phila)</i>. 2008;46(3):243-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18344107\">[PubMed 18344107]</a></p>\n<p>27. Rumack B, Heard K, Green J, et al. Effect of therapeutic doses of acetaminophen (up to 4 g/day) on serum alanine aminotransferase levels in subjects consuming ethanol: systematic review and meta-analysis of randomized controlled trials. <i>Pharmacotherapy</i>. 2012;32(9):784-791. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22851428\">[PubMed 22851428]</a></p>\n<p>28. Thummel KE, Slattery JT, Ro H, et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. <i>Clin Pharmacol Ther</i>. 2000;67(6):591-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10872641\">[PubMed 10872641]</a></p>\n<p>29. Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. <i>Alcohol Clin Exp Res</i>. 1996;20(1)(suppl):25A-28A. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8659683\">[PubMed 8659683]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9781":"<p><b>Title</b> Vitamin K Antagonists / Propacetamol</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction appears most likely with higher propacetamol doses (equivalent to acetaminophen doses exceeding 1.3 to 2 g/day) for multiple consecutive days.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propacetamol may enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with higher doses (equivalent to acetaminophen doses exceeding 1.3 to 2 g/day) for multiple consecutive days. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased anticoagulant effects of vitamin K antagonists if propacetamol is initiated/dose increased, or decreased effects if propacetamol is discontinued/dose decreased. This may be of particular concern in patients expected to receive, or who have been receiving, propacetamol doses corresponding to greater than 1.3 to 2 g/day of acetaminophen for several consecutive days. Advise patients to limit propacetamol and acetaminophen intake to short-term treatment of acute illnesses when possible and to report any regular use to the clinician who is monitoring their anticoagulant therapy.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A case-control study of warfarin-treated patients including cases with an INR of 6 or greater (n=93) and controls with an INR of 1.7 to 3.3 (n=196) found that acetaminophen use was independently associated with the presence of an INR of 6 or greater.<sup>1</sup> The odds were increased more than 10-fold (95% confidence interval: 2.6 to 37.9) among those with acetaminophen intake of more than 9100 mg/week (1.3 g/day). Several prospective, randomized, placebo-controlled studies have also found that acetaminophen may increase the INR in warfarin-treated patients with daily acetaminophen doses of 2 to 4 g/day consumed for 10 to 28 days.<sup>2,3,4,5</sup> Acetaminophen at 4 g/day was associated with average 1.04 to 1.2 unit increases in INR (vs. 0.2 to 0.4 in placebo groups),<sup>2,3</sup> while acetaminophen at 2 to 3 g/day was associated with average INR increases of approximately 0.7 units.<sup>5</sup> These INR increases were observed within 3 to 4 days of acetaminophen initiation.<sup>2,5</sup> On longitudinal study of 171 patients and several published case reports similarly describe increased INR and/or bleeding associated with concurrent use of acetaminophen with warfarin or acenocoumarol.<sup>7,8,9,10,11,12,13,14</sup><br><br>One study examining variability in warfarin dose-requirement, often associated with a greater risk for bleeding, identified concurrent use of acetaminophen as an independent predictor of high dose-variability (i.e., 2-fold or greater difference between lowest and highest weekly warfarin dose).<sup>15</sup><br><br>In contrast, several studies have concluded that there is no significant interaction at usual doses. A pharmacokinetic study of 20 healthy volunteers concluded that acetaminophen 4 g/day for 2 weeks was associated with no significant change in the pharmacokinetics of S- or R-warfarin.<sup>16</sup> Another study in warfarin-treated patients also concluded that there was no evidence of any interaction at acetaminophen doses up to 3 g/day.<sup>17</sup> Several studies have also concluded that, in patients treated with the vitamin K antagonists acenocoumarol or phenprocoumon, usual doses of acetaminophen had no significant impact on anticoagulant effects,<sup>18,19,20</sup> though in one study there was a transient increase in the INR of 0.46 units on day 8 of concurrent therapy (in both 1.5 g/day and 3 g/day acetaminophen groups) but by day 15 there was only an average increase of 0.22 units present, and that increase was limited to the higher-dose (3 g/day) group.<sup>18</sup><br><br>One recent review of this apparent interaction concluded that patients using 2 g/day or more of acetaminophen for 3 or more consecutive days should have their INR tested within 3-5 days of the first acetaminophen dose.<sup>21</sup> It was also recommended that acetaminophen use be considered a possible contributing factor for any otherwise unexplained INR variability. An earlier review of this subject concluded that acetaminophen was still the preferred analgesic and antipyretic for warfarin-treated patients, provided that doses of greater than 1.3 g/day for more than 2 weeks were avoided.<sup>22</sup><br><br>The mechanism of this interaction is unclear, but potential contributing mechanisms have been proposed. One such theory involves enzymatic “shunting” whereby acetaminophen metabolism indirectly leads to decreased warfarin metabolism,<sup>23</sup> though data showing no significant change in S- or R-warfarin pharmacokinetics argues against this theory.<sup>16</sup> Another theory holds that acetaminophen ingestion reduces the concentrations of one or more of the vitamin K-dependent clotting factors, possibly due to irreversible inhibition of vitamin K-dependent carboxylation by the toxic NAPQI metabolite.<sup>24</sup> In support of this theory are several studies finding evidence of reduced clotting factor concentrations in patients exposed to this combination.<sup>3,5,25</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. <i>JAMA</i>. 1998;279(9):657-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9496982\">[PubMed 9496982]</a></p>\n<p>2. Mahe I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. <i>Br J Clin Pharmacol</i>. 2005;59(3):371-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15752384\">[PubMed 15752384]</a></p>\n<p>3. Mahe I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. <i>Haematologica</i>. 2006;91(12):1621-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17145598\">[PubMed 17145598]</a></p>\n<p>4. Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. <i>Pharmacotherapy</i>. 2007;27(5):675-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17461702\">[PubMed 17461702]</a></p>\n<p>5. Zhang Q, Bal-dit-Sollier C, Drouet L, et al. Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. <i>Eur J Clin Pharmacol</i>. 2011;67(3):309-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21191575\">[PubMed 21191575]</a></p>\n<p>6. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. <i>Pharmacotherapy</i>. 2007;27(9):1237-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17723077\">[PubMed 17723077]</a></p>\n<p>7. Justice JL, Kline SS. Analgesics and warfarin. A case that brings up questions and cautions. <i>Postgrad Med</i>. 1988;83(5):217-8, 220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3357860\">[PubMed 3357860]</a></p>\n<p>8. Orme M, Breckenridge A, Cook P. Warfarin and Distalgesic interaction. <i>Br Med J</i>. 1976;1(6003):200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1247776\">[PubMed 1247776]</a></p>\n<p>9. Jones RV. Letter: Warfarin and distalgesic interaction. <i>Br Med J</i>. 1976;1(6007):460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1252799\">[PubMed 1252799]</a></p>\n<p>10. Bartle WR, Blakely JA. Potentiation of warfarin anticoagulation by acetaminophen. <i>JAMA</i>. 1991;265(10):1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1995971\">[PubMed 1995971]</a></p>\n<p>11. Fitzmaurice DA, Murray JA. Potentiation of the anticoagulant effect of warfarin. <i>Postgrad Med J</i>. 1997;73(861):439-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9338037\">[PubMed 9338037]</a></p>\n<p>12. Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. <i>Pharmacotherapy</i>. 2003;23(1):109-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523469\">[PubMed 12523469]</a></p>\n<p>13. Lee R, Wen A, Berube C. Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer. <i>Am J Health Syst Pharm</i>. 2011;68(9):814-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21515865\">[PubMed 21515865]</a></p>\n<p>14. Bagheri H, Bernhard NB, and Montastruc JL, “Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,” Ann Pharmacother, 1999, 33(4):506. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10332548\">[PubMed 10332548]</a></p>\n<p>15. Marrast L, Evans M, Ozonoff A, Henault LE, Rose AJ. Using highly variable warfarin dosing to identify patients at risk for adverse events. <i>Thromb J</i>. 2011;9:14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21985504\">[PubMed 21985504]</a></p>\n<p>16. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. <i>J Clin Pharmacol</i>. 1999;39(1):68-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9987702\">[PubMed 9987702]</a></p>\n<p>17. Antlitz AM, Mead JA Jr, Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. <i>Curr Ther Res Clin Exp</i>. 1968;10(10):501-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4971464\">[PubMed 4971464]</a></p>\n<p>18. Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, “Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,” J Thromb Haemost, 2003, 1(4):714-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12871405\">[PubMed 12871405]</a></p>\n<p>19. Fattinger K, Frisullo R, Masche U, Braunschweig S, Meier PJ, Roos M. No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients. <i>Eur J Clin Pharmacol</i>. 2002;57(12):863-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936705\">[PubMed 11936705]</a></p>\n<p>20. van den Bemt PM, Geven LM, Kuitert NA, Risselada A, Brouwers JR. The potential interaction between oral anticoagulants and acetaminophen in everyday practice. <i>Pharm World Sci</i>. 2002;24(5):201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12426965\">[PubMed 12426965]</a></p>\n<p>21. Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. <i>Blood</i>. 2011;118(24):6269-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911832\">[PubMed 21911832]</a></p>\n<p>22. Shek KL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. <i>Pharmacotherapy</i>. 1999;19(10):1153-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512064\">[PubMed 10512064]</a></p>\n<p>23. Lehmann DE. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. <i>Pharmacotherapy</i>. 2000;20(12):1464-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11130219\">[PubMed 11130219]</a></p>\n<p>24. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. <i>Thromb Haemost</i>. 2004;92(4):797-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15467911\">[PubMed 15467911]</a></p>\n<p>25. Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. <i>Ther Drug Monit</i>. 2000;22(6):742-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11128244\">[PubMed 11128244]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9782":"<p><b>Title</b> Propacetamol / Barbiturates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Patients receiving higher doses (and longer duration) of propacetamol may be at higher risk for experiencing a clinically significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barbiturates may increase the metabolism of Propacetamol. This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of propacetamol and an elevated risk of hepatotoxicity (due to increased concentrations of acetaminophen metabolites), if barbiturates are used concomitantly. This is of particular concern in patients receiving high-dose and/or chronic propacetamol therapy.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> Anticonvulsants may increase the clearance of acetaminophen (a metabolite of propacetamol) by &gt; 40%.<sup>1,2</sup> This is likely due to barbiturate induction of CYP isoenzymes and UDPGTase, leading to increased acetaminophen metabolism. Acetaminophen-induced hepatotoxicity may be enhanced by anticonvulsants due to increased production of toxic acetaminophen metabolites which exceed glutathione binding capacity (the mechanism by which the metabolites are cleared). Acetaminophen concentrations may be relatively low, complicating the diagnosis and delaying the appropriate administration of acetylcysteine.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Perucca E and Richens A, “Paracetamol Disposition in Normal Subjects and in Patients Treated With Antiepileptic Drugs,” <i>Br J Clin Pharmacol</i>, 1979, 7(2):201-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=760753\">[PubMed 760753]</a></p>\n<p>2. Miners JO, Attwood J, and Birkett DJ, “Determinants of Acetaminophen Metabolism: Effect of Inducers and Inhibitors of Drug Metabolism on Acetaminophen's Metabolic Pathways,” <i>Clin Pharmacol Ther</i>, 1984, 35(4):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p>3. Minton NA, Henry JA, and Frankel RJ, “Fatal Paracetamol Poisoning in an Epileptic,” <i>Hum Toxicol</i>, 1988, 7(1):33-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3346037\">[PubMed 3346037]</a></p>\n<p>4. McClements BM, Hyland M, Callender ME, et al, “Management of Paracetamol Poisoning Complicated by Enzyme Induction Due to Alcohol or Drugs,” <i>Lancet</i>, 1990, 335(8704):1526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1972451\">[PubMed 1972451]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9783":"<p><b>Title</b> Busulfan / Propacetamol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propacetamol may increase the serum concentration of Busulfan. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased busulfan concentrations and systemic effects in patients who receive propacetamol concurrent with, or in the 72 hours prior to, busulfan.</p> \n<p><b>Discussion</b> Busulfan prescribing information states that acetaminophen (a metabolite of propacetamol) administration concurrent with, or in the 72 hours prior to, busulfan could modify busulfan clearance.<sup>1,2</sup> Acetaminophen could theoretically deplete glutathione concentrations in blood and tissues, decreasing the amounts available for busulfan conjugation. Preliminary data from a population pharmacokinetic study did not indicate a difference in busulfan clearance in hematopoietic stem cell transplant recipients who received acetaminophen (N=19) compared to those who did not (N=84).<sup>3</sup> Nonetheless, busulfan clearance does appear to correlate with plasma glutathione concentrations,<sup>4</sup> so caution is warranted until more definitive human data become available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Busulfex (busulfan). Rockville, MD: Otsuka America Pharmaceutical, Inc., April 2011.</p>\n<p>2. Product monograph. Busulfex (busulfan). Saint-Laurent, QC: Otsuka Canada Pharmaceutical Inc., July 2011.</p>\n<p>3. Nguyen L, Leger F, Lennon S, et al, “Intravenous Busulfan in Adults Prior to Haematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study,” <i>Cancer Chemother Pharmacol</i>, 2006, 57(2):191-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16133536\">[PubMed 16133536]</a></p>\n<p>4. Almog S, Kurnik D, Shimoni A, et al, “Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination,” <i>Biol Blood Marrow Transplant</i>, 2011, 17(1):117-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20601034\">[PubMed 20601034]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9784":"<p><b>Title</b> Propacetamol / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Patients receiving higher doses (and longer duration) of propacetamol may be at higher risk for experiencing a clinically significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may increase the metabolism of Propacetamol. This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of propacetamol and an elevated risk of hepatotoxicity (due to increased concentrations of acetaminophen metabolites), if carbamazepine is used concomitantly. This is of particular concern in patients receiving high-dose and/or chronic propacetamol therapy.</p> \n<p><b>Discussion</b> Anticonvulsants may increase acetaminophen (a metabolite of propacetamol) clearance by &gt;40%.<sup>1,2</sup> This is likely due to carbamazepine induction of CYP isoenzymes and UDPGTase leading to acetaminophen metabolism. Acetaminophen-induced hepatotoxicity may be enhanced by anticonvulsants due to increased production of toxic acetaminophen metabolites which exceed glutathione binding capacity (the mechanism by which the metabolites are cleared). Acetaminophen concentrations may be relatively low, complicating the diagnosis and delaying the appropriate administration of acetylcysteine. This has been demonstrated with phenobarbital and phenytoin.<sup>3,4</sup> Carbamazepine concentrations do not appear to be affected by acetaminophen.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Perucca E and Richens A, “Paracetamol Disposition in Normal Subjects and in Patients Treated With Antiepileptic Drugs,” <i>Br J Clin Pharmacol</i>, 1979, 7(2):201-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=760753\">[PubMed 760753]</a></p>\n<p>2. Miners JO, Attwood J, and Birkett DJ, “Determinants of Acetaminophen Metabolism: Effect of Inducers and Inhibitors of Drug Metabolism on Acetaminophen's Metabolic Pathways,” <i>Clin Pharmacol Ther</i>, 1984, 35(4):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p>3. Minton NA, Henry JA, and Frankel RJ, “Fatal Paracetamol Poisoning in an Epileptic,” <i>Hum Toxicol</i>, 1988, 7(1):33-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3346037\">[PubMed 3346037]</a></p>\n<p>4. McClements BM, Hyland M, Callender ME, et al, “Management of Paracetamol Poisoning Complicated by Enzyme Induction Due to Alcohol or Drugs,” <i>Lancet</i>, 1990, 335(8704):1526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1972451\">[PubMed 1972451]</a></p>\n<p>5. Neuvonen PJ, Lehtovaara R, Bardy A, et al, “Antipyretic Analgesics in Patients on Antiepileptic Drug Therapy,” <i>Eur J Clin Pharmacol</i>, 1979, 15(4):263-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=314381\">[PubMed 314381]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9785":"<p><b>Title</b> Chloramphenicol (Systemic) / Propacetamol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propacetamol may increase the serum concentration of Chloramphenicol (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor chloramphenicol therapy particularly closely if used together with propacetamol, particularly monitoring patients for evidence of chloramphenicol toxicity.</p> \n<p><b>Discussion</b> The chloramphenicol half-life was prolonged by more than 4.6-fold (from 3.25 hours to 15 hours) with concurrent acetaminophen (a metabolite of propacetamol, 100 mg IV) in a study of 6 adult patients being treated in an intensive care unit.<sup>1</sup> Conversely, studies in acutely ill children who were being treated with chloramphenicol with (n=8) or without (n=18) concurrent acetaminophen and in adults (n=5) being treated with chloramphenicol who were evaluated with and without acetaminophen both reported no significant differences in chloramphenicol pharmacokinetics associated with acetaminophen use.<sup>2,3</sup> Another study reported increased chloramphenicol clearance, decreased half-life, and decreased maximum serum concentration in children (n=5) who received both chloramphenicol (80 mg/kg/day IV) and acetaminophen (50 mg/kg/day, given every 6 hours).<sup>4</sup> It has been suggested that this conflicting finding may reflect simply the decrease in chloramphenicol concentrations that have been reported by some authors to happen between initial chloramphenicol doses and what is observed at steady-state.<sup>5</sup> Other studies of this interaction have, however, reported no significant differences between first-dose and steady-state pharmacokinetics of chloramphenicol.<sup>2</sup><br><br>The degree to which acetaminophen truly impacts chloramphenicol pharmacokinetics is unclear. Despite early reports of an increased chloramphenicol half-life with acetaminophen, more recent studies have reported either no change or a decrease in half-life, raising questions about the validity of previous reports. The mechanism for any such interaction is not certain, but acetaminophen inhibition of chloramphenicol glucuronidation is a possible explanation, as acetaminophen does undergo considerable conjugative metabolism, and thus could compete with other drugs for these metabolic enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Buchanan N, Moodley GP. Interaction between chloramphenicol and paracetamol. <i>Br Med J</i>. 1979;2(6185):307-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=476439\">[PubMed 476439]</a></p>\n<p>2. Kearns GL, Bocchini JA Jr, Brown RD, Cotter DL, Wilson JT. Absence of a pharmacokinetic interaction between chloramphenicol and acetaminophen in children. <i>J Pediatr</i>. 1985;107(1):134-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4009329\">[PubMed 4009329]</a></p>\n<p>3. Stein CM, Thornhill DP, Neill P, Nyazema NZ. Lack of effect of paracetamol on the pharmacokinetics of chloramphenicol. <i>Br J Clin Pharmacol</i>. 1989;27(2):262-264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2713219\">[PubMed 2713219]</a></p>\n<p>4. Spika JS, Davis DJ, Martin SR, Beharry K, Rex J, Aranda JV. Interaction between chloramphenicol and acetaminophen. <i>Arch Dis Child</i>. 1986;61(11):1121-1124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3789791\">[PubMed 3789791]</a></p>\n<p>5. Choonara IA. Interaction between chloramphenicol and acetaminophen. <i>Arch Dis Child</i>. 1987;62(3):319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3566335\">[PubMed 3566335]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9786":"<p><b>Title</b> Propacetamol / Dasatinib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dasatinib may enhance the hepatotoxic effect of Propacetamol. Dasatinib may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, acetaminophen concentrations may increase. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> As possible, consider less frequent and/or lower daily doses of propacetamol in patients who are also taking dasatinib. Patients exposed to this combination, and particularly those with greater propacetamol exposure, should be monitored for signs/symptoms of liver toxicity.</p> \n<p><b>Discussion</b> An in vitro study using human liver microsomes concluded that the tyrosine kinase inhibitors dasatinib, imatinib, and sunitinib were all potent inhibitors of glucuronidation of acetaminophen (a metabolite of propacetamol),<sup>1</sup> suggesting a possible pharmacokinetic interaction between these agents and acetaminophen. Evidence for more of a pharmacodynamic mechanism for this apparent interaction is also available. An in vitro study of dasatinib metabolism concluded that dasatinib metabolism results in the formation of a highly reactive intermediate, similar to that formed from acetaminophen metabolism.<sup>2</sup> Formation of such a reactive metabolite could result in excessive hepatocellular damage, particularly when given with another hepatotoxic agent such as acetaminophen.<br><br>Though the clinical significance of these in vitro findings are not clear, case reports have described fatal hepatotoxicity associated with acetaminophen-imatinib and acetaminophen-sunitinib-levothyroxine.<sup>3,4</sup> Also, a study in mice found evidence of more hepatic toxicity with concurrent use of imatinib and acetaminophen than with either drug alone.<sup>5</sup> Although it is not certain what role, if any, acetaminophen had in these cases (since both imatinib and sunitinib have been independently associated with hepatotoxicity), National Comprehensive Cancer Network practice guidelines for CML do include a warning concerning the potential acetaminophen--imatinib interaction and recommend a maximum acetaminophen dose of 1300 mg per day for patients receiving imatinib.<sup>6</sup> No such specific recommendation is included for sunitinib or dasatinib, but limiting the acetaminophen dose when possible certainly appears to be a prudent preventive measure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu Y, Ramirez J, Ratain MJ, “Inhibition of Acetaminophen Glucuronidation by Tyrosine Kinase Inhibitors,” <i>Br J Clin Pharmacol</i>, 2011, Jan 14 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21235620\">[PubMed 21235620]</a></p>\n<p>2. Li X, He Y, Ruiz CH, Koenig M, et al, “Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways,” <i>Drug Metab Dispos</i>, 2009, 37(6):1242-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19282395\">[PubMed 19282395]</a></p>\n<p>3. Weise AM, Liu CY, Shields AF, “Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and Levothyroxine,” <i>Ann Pharmacother</i>, 2009, 43(4):761-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336648\">[PubMed 19336648]</a></p>\n<p>4. Ridruejo E, Cacchione R, Villamil AG, et al, “Imatinib-Induced Fatal Acute Liver Failure,” <i>World J Gastroenterol</i>, 2007, 13(48):6608-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18161937\">[PubMed 18161937]</a></p>\n<p>5. Nassar I, Pasupati T, Judson JP, et al, “Histopathological Study of the Hepatic and Renal Toxicity Associated with the Co-administration of Imatinib and Acetaminophen in a Preclinical Mouse Model,” <i>Malays J Pathol</i>, 2010, 32(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20614720\">[PubMed 20614720]</a></p>\n<p>6. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. V.2.2009. Available through www.nccn.org (accessed 10/27/2008).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9787":"<p><b>Title</b> Propacetamol / Fosphenytoin-Phenytoin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Patients receiving larger doses (or longer-term use) of propacetamol may be at higher risk for experiencing a clinically significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of Propacetamol. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of its toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for hepatotoxicity when large doses (or long term use) of propacetamol are used in a patient taking phenytoin or fosphenytoin. Decreased propacetamol effects may also be seen.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> In one study, the steady-state plasma concentration of acetaminophen (APAP, a metabolite of propacetamol) was 17% lower after treatment with phenytoin (100 mg every 8 hours for 11 days).<sup>1</sup> In other clinical studies comparing epileptic patients taking phenytoin (either alone or combined with other agents) with healthy controls, the APAP AUC was 31% to 41% lower, clearance was 46% higher, and the half-life was 21% to 28% shorter in the epileptic patients.<sup>2,3,4</sup> This decreased exposure could reduce therapeutic response to acetaminophen, but such an effect has not been reported. Of more concern is the possibility of increased production of the toxic acetaminophen metabolite (N-acetyl-p-benzoquinone imine [NAPQI]) in the presence of phenytoin therapy. Several case reports describe patients taking phenytoin who experienced liver toxicity (ranging from elevations in liver function tests, coagulopathy, encephalopathy, fulminant liver failure requiring transplantation, and death) after acute ingestion of acetaminophen (25 g to 45 g).<sup>5,6,7</sup> In all cases, acetaminophen levels were relatively low and only one patient received N-acetylcysteine (NAC). The authors of each report suggest that the severity of liver dysfunction experienced was out of proportion to the measured serum APAP level suggesting phenytoin played a contributory role. Another case report describes a patient on phenytoin therapy who experienced elevations in liver function tests after ingesting 1,300 mg to 6,200 mg of APAP daily for 10 days.<sup>8</sup> Phenytoin concentrations do not appear to be affected by acetaminophen.<sup>9</sup><br><br>The exact mechanism of an interaction between acetaminophen and phenytoin is not clear. Normally, 80% to 90% of APAP undergoes conjugation via 5-diphosphate-glucuronosyltranferases (UGTs) to inactive, nontoxic metabolites. Approximately 10% of the dose is oxidized via CYP enzymes to the toxic NAPQI metabolite. NAPQI is rapidly conjugated, in the presence of adequate stores of glutathione, to form additional nontoxic metabolites that are then excreted. It has been proposed that phenytoin may induce CYP enzymes, thus increasing the formation of NAPQI.<sup>8</sup> Additionally, in vitro studies suggest that phenytoin may inhibit several UGTs and shunt metabolism to increase formation of NAPQI.<sup>10,11</sup> However, other studies suggest that phenytoin may induce UGTs rather than inhibit them,<sup>12,13</sup> and an increase in the formation of the glucoronide conjugate has been reported with phenytoin use.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cunningham JL, Evans DA. Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? <i>Br J Clin Pharmacol</i>. 1981;11(6):591-595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7272175\">[PubMed 7272175]</a></p>\n<p>2. Perucca E, Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. <i>Br J Clin Pharmacol</i>. 1979;7(2):201-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=760753\">[PubMed 760753]</a></p>\n<p>3. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. <i>Clin Pharmacol Ther</i>. 1984;35(4):480-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p>4. Prescott LF, Critchley JA, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. <i>Br J Clin Pharmacol</i>. 1981;12(2):149-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7306429\">[PubMed 7306429]</a></p>\n<p>5. Minton NA, Henry JA, Frankel RJ. Fatal paracetamol poisoning in an epileptic. <i>Hum Toxicol</i>. 1988;7(1):33-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3346037\">[PubMed 3346037]</a></p>\n<p>6. McClements BM, Hyland M, Callender ME, Blair TL. Management of paracetamol poisoning complicated by enzyme induction due to alcohol or drugs. <i>Lancet</i>. 1990;335(8704):1526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1972451\">[PubMed 1972451]</a></p>\n<p>7. Suchin SM, Wolf DC, Lee Y, et al. Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation. <i>Dig Dis Sci</i>. 2005;50(10):1836-1838. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16187183\">[PubMed 16187183]</a></p>\n<p>8. Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen heptatoxcity: case report and review of the literature. <i>Pharmacotherapy</i>. 2000;20(2):229-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10678302\">[PubMed 10678302]</a></p>\n<p>9. Neuvonen PJ, Lehtovaara R, Bardy A, Elomaa E. Antipyretic analgesics in patients on antiepileptic drug therapy. <i>Eur J Clin Pharmacol</i>. 1979;15(4):263-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=314381\">[PubMed 314381]</a></p>\n<p>10. Kostrubsky SE, Sinclair JF, Strom SC, et al. Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. <i>Toxicol Sci</i>. 2005;87(1):146-155. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15933229\">[PubMed 15933229]</a></p>\n<p>11. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkami S, Kostrubsky S. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9, and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. <i>Chem Res Toxicol</i>. 2006;19(5):701-709. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16696573\">[PubMed 16696573]</a></p>\n<p>12. Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. <i>Eur J Clin Pharmacol</i>. 1987;31(6):677-683. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3556375\">[PubMed 3556375]</a></p>\n<p>13. Bock KW, Bock-Hennig BS. Differential induction of human liver UDP-glucuronosyltransferase activities by phenobarbital-type inducers. <i>Biochem Pharmacol</i>. 1987;36(23):4137-4143. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2825716\">[PubMed 2825716]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9788":"<p><b>Title</b> Imatinib / Propacetamol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propacetamol may enhance the hepatotoxic effect of Imatinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use propacetamol cautiously in patients receiving imatinib, and consider enhanced monitoring of liver function tests in patients who receive these agents in combination.</p> \n<p><b>Discussion</b> A published case report describes a 51-year-old patient with chronic myelogenous leukemia who developed severe hepatitis several months after starting therapy with imatinib.<sup>1</sup> The patient had also been regularly taking acetaminophen (a metabolite of propacetamol, 500-1000mg/day). Following progressive worsening of liver function, the patient experienced a cardiac arrest and died. Imatinib U.S. prescribing information also describes a case of fatal liver failure in a patient receiving imatinib with acetaminophen, although it is not clear whether this case is different from one described in the published report.<sup>2</sup> Fatal liver toxicity has also been described during use of a different tyrosine kinase inhibitor, sunitinib, together with acetaminophen and levothyroxine.<sup>3</sup> The authors propose that concurrent use of sunitinib and acetaminophen may have had a significant role in the development of hepatotoxicity, although levothyroxine appeared to be the immediate precipitant. <br><br>The mechanism by which certain tyrosine kinase inhibitors may interact with acetaminophen to increase the risk of hepatotoxicity is uncertain. A study in mice found evidence of enhanced hepatotoxicity during administration of imatinib with acetaminophen compared to either drug alone, in support of a potential interaction.<sup>4</sup> Imatinib inhibits acetaminophen metabolism (via O-glucuronidation) in vitro,<sup>2,5</sup> although in a clinical study the coadministraiton of imatinib (400 mg/day for 8 days) with a single dose of acetaminophen (1,000 mg) had no impact on pharmacokinetic variables of either drug.<sup>2,6</sup> A pharmacodynamic mechanism of interaction is also possible. An in vitro study of dasatinib metabolism concluded that dasatinib metabolism results in the formation of a highly reactive intermediate, similar to that formed from acetaminophen metabolism.<sup>7</sup> Formation of such a reactive metabolite could result in excessive hepatocellular damage, particularly when given with another hepatotoxic agent such as acetaminophen.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ridruejo E, Cacchione R, Villamil AG, et al, “Imatinib-Induced Fatal Acute Liver Failure,” <i>World J Gastroenterol</i>, 2007, 13(48):6608-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18161937\">[PubMed 18161937]</a></p>\n<p>2. Prescribing information. Gleevec (imatinib). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2/2013.</p>\n<p>3. Weise AM, Liu CY, Shields AF, “Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and Levothyroxine,” <i>Ann Pharmacother</i>, 2009, 43(4):761-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336648\">[PubMed 19336648]</a></p>\n<p>4. Nassar I, Pasupati T, Judson JP, et al, “Histopathological Study of the Hepatic and Renal Toxicity Associated with the Co-administration of Imatinib and Acetaminophen in a Preclinical Mouse Model,” <i>Malays J Pathol</i>, 2010, 32(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20614720\">[PubMed 20614720]</a></p>\n<p>5. Liu Y, Ramirez J, Ratain MJ, “Inhibition of Acetaminophen Glucuronidation by Tyrosine Kinase Inhibitors,” <i>Br J Clin Pharmacol</i>, 2011, Jan 14 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21235620\">[PubMed 21235620]</a></p>\n<p>6. Kim DW, Tan EY, Jin Y, et al, “Effects of Imatinib Mesylate on the Pharmacokinetics of Paracetamol (Acetaminophen) in Korean Patients with Chronic Myelogenous Leukaemia,” <i>Br J Clin Pharmacol</i>, 2011, 71(2):199-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21219400\">[PubMed 21219400]</a></p>\n<p>7. Li X, He Y, Ruiz CH, Koenig M, et al, “Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways,” <i>Drug Metab Dispos</i>, 2009, 37(6):1242-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19282395\">[PubMed 19282395]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9789":"<p><b>Title</b> Propacetamol / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may enhance the hepatotoxic effect of Propacetamol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of hepatotoxicity if these two agents are used concomitantly. Use of a different analgesic/antipyretic may be considered (eg, nonsteroidal anti-inflammatory agents, or aspirin).</p> \n<p><b>Discussion</b> Case reports. Patients being treated with isoniazid have developed evidence of liver damage after receiving high, single doses of acetaminophen (a metabolite of propacetamol, 3.25-11.5 g), or daily doses as low as 2-6 g. Concomitant use of rifampin and pyrazinamide may have played a role in some cases.<sup>1,2,3</sup> The mechanism of this interaction is unknown. The likelihood that isoniazid may increase the production of toxic acetaminophen metabolites has been debated.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Murphy R, Swartz R, and Watkins PB, “Severe Acetaminophen Toxicity in a Patient Receiving Isoniazid,” <i>Ann Intern Med</i>, 1990, 113(10):799-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2240884\">[PubMed 2240884]</a></p>\n<p>2. Moulding TS, Redeker AG, and Kanel GC, “Acetaminophen, Isoniazid, and Hepatic Toxicity,” <i>Ann Intern Med</i>, 1991, 114(5):431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1992890\">[PubMed 1992890]</a></p>\n<p>3. Nolan CM, Sandblom RE, Thummel KE, et al, “Hepatotoxicity Associated With Acetaminophen Usage in Patients Receiving Multiple Drug Therapy For Tuberculosis,” <i>Chest</i>, 1994, 105(2):408-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7508362\">[PubMed 7508362]</a></p>\n<p>4. Epstein MM, Nelson SD, Slattery JT, et al, “Inhibition of the Metabolism of Paracetamol by Isoniazid,” <i>Br J Clin Pharmacol</i>, 1991, 31(2):139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2049229\">[PubMed 2049229]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9790":"<p><b>Title</b> Propacetamol / MetyraPONE</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The clinical significance of this interaction may be greater with larger propacetamol doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyraPONE may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, metyrapone may increase acetaminophen exposure. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism toward the oxidative route that produces a hepatotoxic metabolite. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution with concurrent use of metyrapone and propacetamol; the risk is likely to be greatest in patients using moderate or high doses of propacetamol.</p> \n<p><b>Discussion</b> Metyrapone prescribing information cautions that metyrapone may increase the risk for acetaminophen (a metabolite of propacetamol) toxicity due to the ability of metyrapone to inhibit the glucuronidation of acetaminophen.<sup>1</sup> Study data from both humans and rats have shown that metyrapone inhibits acetaminophen glucuronidation.<sup>2,3</sup> The impact that such an impairment of this conjugation-type metabolism has on the oxidation of acetaminophen to its toxic NAPQI metabolite is unclear, but at least one study has suggested that enhanced oxidative metabolism is possible.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Metopirone (metyrapone). East Hanover, NJ: Novartis Pharmaceuticals Corporation, November 2010.</p>\n<p>2. Galinsky RE, Nelson EB, Rollins DE, “Pharmacokinetic Consequences and Toxicologic Implications of Metyrapone-Induced Alterations of Acetaminophen Elimination in Man,” <i>Eur J Clin Pharmacol</i>, 1987, 33(4):391-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3443145\">[PubMed 3443145]</a></p>\n<p>3. Galinsky RE, Corcoran GB, “Suppression of Acetaminophen Conjugation and of Conjugate Elimination in the Rat by Metyrapone, A Classical P-450 Inhibitor,” <i>Drug Metab Dispos</i>, 1988, 16(3):348-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2900724\">[PubMed 2900724]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9791":"<p><b>Title</b> Propacetamol / Mipomersen</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is specific for higher propacetamol doses (equivalent to 4 g/day or more of acetaminophen) and more frequent use (3 days/week or more).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mipomersen may enhance the hepatotoxic effect of Propacetamol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of mipomersen together with other drugs that are associated with hepatotoxicity. Of specific concern with concurrent propacetamol is the use of higher doses (equivalent to 4 g/day or more of acetaminophen) and more frequent use (3 days or more per week). Patients being treated with mipomersen who use this much propacetamol should be monitored more closely for evidence of hepatotoxicity.</p> \n<p><b>Discussion</b> According to the mipomersen prescribing information, mipomersen treatment is associated with hepatic fat accumulation, which may cause or worsen hepatic injury.<sup>1</sup> Hepatic steatosis (i.e., excessive fat accumulation) is a known risk factor for advanced liver disease. Considering the known potential for hepatotoxicity with propacetamol, extra caution should be used considering the use of mipomersen together with concurrent propacetamol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Kynamro (mipomersen). Cambridge, MA: Genzyme Corporation, 1/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9792":"<p><b>Title</b> Phenylephrine (Systemic) / Propacetamol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propacetamol may increase the serum concentration of Phenylephrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.</p> \n<p><b>Discussion</b> According to a published correspondence, the phenylephrine AUC was increased by an average of 2-fold, and the phenyephrine Cmax was increased by an average of 4-fold with concurrent acetaminophen (a metabolite of propacetamol) in three randomized, open-label, cross-over studies where an unspecified number volunteers received a three drug combination of 1000 mg acetaminophen, 300 mg ibuprofen, and 10 mg phenylephrine compared to phenylephrine (10 mg) alone.<sup>1</sup> According to the authors of the correspondence, ibuprofen was excluded as a potential cause of increased phenylephrine concentrations, though the specific data used to rule-out a contribution by ibuprofen were not presented.<br><br>Phenylephrine with acetaminophen has been described as safe in a phase III randomized, double-blinded, placebo-controlled controlled study testing the combination of 400 mg acetaminophen, 4.0 mg chlorphenamine, and 4.0 mg phenylephrine every 4 hours for 2-3 days among 146 subjects.<sup>2</sup> The side effect profile, including heart rate and blood pressure, were comparable in the treatment and placebo groups, though the phenylephrine and acetaminophen strengths were lower than those mentioned in the correspondence. <br><br>The proposed mechanism for this potential interaction is inhibition of phenylephrine sulfation in the intestinal wall by acetaminophen. Sulfation is a major metabolic pathway for phenylephrine, involving approximately 46% of the total phenylephrine parent drug.<sup>3</sup> An in vitro study showed that different acetaminophen doses decrease ethinyloestradiol sulfation by 32-80%, and although this study did not specifically involve phenylephrine, these findings suggest that this mechanism may explain the observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Atkinson HC, Stanescu I, Anderson BJ. Increased phenylephrine plasma levels with administration of acetaminophen. <i>N Engl J Med</i>. 2014;370(12):1171-1172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24645960\">[PubMed 24645960]</a></p>\n<p>2. Picon PD, Costa MB, da Veiga Picon R, et al. Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial. <i>BMC Infect Dis</i>. 2013;13:556. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24261438\">[PubMed 24261438]</a></p>\n<p>3. Rogers SM, Back DJ, Orme ML. Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers. <i>Br J Clin Pharmacol</i>. 1987;23(6):727-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3606932\">[PubMed 3606932]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9793":"<p><b>Title</b> Propacetamol / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Probenecid may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, accetaminophen exposure may be increased. Probenecid may also limit the formation of at least one major non-toxic acetaminophen metabolite, possibly increasing the formation of the toxic NAPQI metabolite. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider limiting the use of propacetamide in patients who are also taking probenecid. Because probenecid use may be associated with reduced clearance of acetaminophen (a metabolite of propacetamol) to one of its non-toxic metabolites, patients may be at an increased risk for toxicity, even at lower propacetamol doses.</p> \n<p><b>Discussion</b> Mean acetaminophen (a metabolite of propacetamol) clearance was approximately 45% lower and the mean urinary excretion of acetaminophen glucuronide was 68-79% lower with concurrent probenecid in two separate studies in healthy volunteers.<sup>1,2</sup> Additionally, concurrent probenecid was associated with a mean 72% increase in acetaminophen half-life (4.3 hrs vs. 2.5 hrs).<sup>1</sup><br><br>The results of several in vitro studies support the findings of these studies in healthy volunteers.<sup>3,4,5</sup><br><br>The exact mechanism(s) of this interaction is unknown, but probenecid appears to inhibit the formation, and possibly the excretion, of acetaminophen glucuronide.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Abernethy DR, Greenblatt DJ, Ameer B, et al, “Probenecid Impairment of Acetaminophen and Lorazepam Clearance: Direct Inhibition of Ether Glucuronide Formation,” <i>J Pharmacol Exp Ther</i>, 1985, 234(2):345-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4020675\">[PubMed 4020675]</a></p>\n<p>2. Kamali F, “The Effect of Probenecid on Paracetamol Metabolism and Pharmacokinetics,” <i>Eur J Clin Pharmacol</i>, 1993, 45(6):551-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8157041\">[PubMed 8157041]</a></p>\n<p>3. Turner KC, Brouwer KL, “In Vitro Mechanisms of Probenecid-Associated Alterations in Acetaminophen Glucuronide Hepatic Disposition,” <i>Drug Metab Dispos</i>, 1997, 25(9):1017-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9311615\">[PubMed 9311615]</a></p>\n<p>4. von Moltke LL, Manis M, Harmatz JS, et al, “Inhibition of Acetaminophen and Lorazepam Glucuronidation In Vitro by Probenecid,” <i>Biopharm Drug Dispos</i>, 1993, 14(2):119-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453022\">[PubMed 8453022]</a></p>\n<p>5. Savina PM, Brouwer KL, “Probenecid-Impaired Biliary Excretion of Acetaminophen Glucuronide and Sulfate in the Rat,” <i>Drug Metab Dispos</i>, 1992, 20(4):496-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1356724\">[PubMed 1356724]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9794":"<p><b>Title</b> Propacetamol / SORAfenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> SORAfenib may enhance the hepatotoxic effect of Propacetamol. SORAfenib may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, acetaminophen exposure may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> As possible, consider less frequent and/or lower daily doses of propacetamol in patients who are also taking sorafenib. Patients exposed to this combination, and particularly those with greater propacetamol exposure, should be monitored for signs/symptoms of liver toxicity.</p> \n<p><b>Discussion</b> A case report describes fatal liver toxicity associated with concurrent use of sunitinib, acetaminophen, and levothyroxine.<sup>1</sup> Though levothyroxine may have been the immediate precipitant of the observed toxicity in this case, it is suspected that concurrent use of sunitinib and acetaminophen contributed. Another published report describes a case of fatal liver toxicity associated with concurrent use of the tyrosine kinase inhibitor imatininb and acetaminophen.<sup>2</sup> Similarly, a study in mice found evidence of more hepatic toxicity with concurrent use of imatinib and acetaminophen than with either drug alone.<sup>3</sup><br><br>Although it is not certain what role, if any, acetaminophen had in these cases (since both imatinib and sunitinib have been independently associated with hepatotoxicity), National Comprehensive Cancer Network practice guidelines for CML include a warning concerning the potential acetaminophen--imatinib interaction and recommend a maximum acetaminophen dose of 1300 mg per day for patients receiving imatinib.<sup>4</sup> No such specific recommendation is included for sunitinib, but limiting the acetaminophen dose when possible certainly appears to be a prudent preventive measure.<br><br>The mechanism by which certain tyrosine kinase inhibitors such as sunitinib or imatinib may interact with acetaminophen to cause a greater risk of hepatotoxicity is uncertain. An in vitro study using human liver microsomes concluded that dasatinib, imatinib, and sunitinib were all potent inhibitors of acetaminophen glucuronidation,<sup>5</sup> suggesting a possible pharmacokinetic mechanism for the observed interaction. In contrast, single-dose (1000 mg) acetaminophen pharmacokinetics were not significantly altered when administered following pre-treatment with imatinib (400 mg/day x 7 days) (n=12).<sup>6</sup> Evidence for more of a pharmacodynamic mechanism for this apparent interaction is also available. An in vitro study of dasatinib metabolism concluded that dasatinib metabolism results in the formation of a highly reactive intermediate, similar to that formed from acetaminophen metabolism.<sup>7</sup> Formation of such a reactive metabolite could result in excessive hepatocellular damage, particularly when given with another hepatotoxic agent such as acetaminophen.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Weise AM, Liu CY, Shields AF, “Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and Levothyroxine,” <i>Ann Pharmacother</i>, 2009, 43(4):761-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336648\">[PubMed 19336648]</a></p>\n<p>2. Ridruejo E, Cacchione R, Villamil AG, et al, “Imatinib-Induced Fatal Acute Liver Failure,” <i>World J Gastroenterol</i>, 2007, 13(48):6608-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18161937\">[PubMed 18161937]</a></p>\n<p>3. Nassar I, Pasupati T, Judson JP, et al, “Histopathological Study of the Hepatic and Renal Toxicity Associated with the Co-administration of Imatinib and Acetaminophen in a Preclinical Mouse Model,” <i>Malays J Pathol</i>, 2010, 32(1):1-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20614720\">[PubMed 20614720]</a></p>\n<p>4. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. V.2.2009. Available through www.nccn.org (accessed 10/27/2008).</p>\n<p>5. Liu Y, Ramirez J, Ratain MJ, “Inhibition of Acetaminophen Glucuronidation by Tyrosine Kinase Inhibitors,” <i>Br J Clin Pharmacol</i>, 2011, Jan 14 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21235620\">[PubMed 21235620]</a></p>\n<p>6. Kim DW, Tan EY, Jin Y, et al, “Effects of Imatinib Mesylate on the Pharmacokinetics of Paracetamol (Acetaminophen) in Korean Patients with Chronic Myelogenous Leukaemia,” <i>Br J Clin Pharmacol</i>, 2011, 71(2):199-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21219400\">[PubMed 21219400]</a></p>\n<p>7. Li X, He Y, Ruiz CH, Koenig M, et al, “Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways,” <i>Drug Metab Dispos</i>, 2009, 37(6):1242-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19282395\">[PubMed 19282395]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9795":"<p><b>Title</b> Propacetamol / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sulfinpyrazone may decrease serum concentrations of the active metabolite(s) of Propacetamol. Specifically, acetaminophen exposure may decrease. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Sulfinpyrazone has been noted to increase clearance of acetaminophen (a metabolite of propacetamol) by approximately 23%, presumably due to increased glucuronidation (ie, detoxifying pathway).<sup>1</sup> It is doubtful that any reduced clinical response to acetaminophen would be appreciated. Suggestions that the risk of acetaminophen-induced hepatotoxicity have not been validated in the literature.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Miners JO, Attwood J, and Birkett DJ, “Determinants of Acetaminophen Metabolism: Effect of Inducers and Inhibitors of Drug Metabolism on Acetaminophen's Metabolic Pathways,” <i>Clin Pharmacol Ther</i>, 1984, 35(4):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9796":"<p><b>Title</b> Simvastatin / Sildenafil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sildenafil may enhance the adverse/toxic effect of Simvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased simvastatin toxicities (eg, rhabdomyolysis) if combined with sildenafil.</p> \n<p><b>Discussion</b> A single case report describes a simvastatin-stable patient who experienced severe muscle aches beginning approximately 8 hours after the administration of a single dose of sildenafil.<sup>1</sup> The symptoms resolved over a period of 3 days and laboratory analysis (after all symptoms had subsided) showed mildly elevated creatinine phosphokinase (CPK) and blood urea nitrogen (BUN).<sup>1</sup><br><br>The mechanism of this interaction is unknown. Both simvastatin and sildenafil are metabolized by CYP3A4 and competition for this enzyme may have contributed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gutierrez CA. Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? <i>Am Fam Physican</i>. 2001;63(4):636-637. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11237079\">[PubMed 11237079]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9797":"<p><b>Title</b> Rosuvastatin / Sildenafil</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sildenafil may enhance the adverse/toxic effect of Rosuvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A single case report describes a 66-year-old man who had been taking rosuvastatin for 5 months and experienced rhabdomyolysis and priapism 1 hour after a single dose of sildenafil.<sup>1</sup> He developed acute renal failure with creatinine phosphokinase (CPK) levels greater than 19,000 units/L that gradually resolved after discontinuation of both sildenafil and rosuvastatin.<sup>1</sup> <br><br>The mechanism of this interaction is unknown. Muscle toxicity is a common adverse event associated with rosuvastatin therapy and a single case report describes a 45-year-old male who experienced rhabdomyolysis after ingestion of an overdose of sildenafil 250 mg.<sup>2</sup> Therefore, the risk of rhabdomyolysis may be additive when these agents are combined.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pennisi G, Vacante M, Russo C, Malaguarnera M. Rhabdomyolysis induced by rosuvastatin and sildenafil. <i>South Med J</i>. 2010;103(10):1052-1054. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20818298\">[PubMed 20818298]</a></p>\n<p>2. Oh DJ. Sildenafil overdose can cause rhabdomyolysis and subjective visual perception changes. <i>Nephrology (Carlton)</i>. 2014;19(4):258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24661860\">[PubMed 24661860]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9798":"<p><b>Title</b> Rolapitant / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid rolapitant use in patients requiring chronic administration of strong CYP3A4 inducers. Monitor for reduced rolapitant response and the need for alternative or additional antiemetic therapy even with shorter-term use of such inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in rolapitant US prescribing information, coadministration of rifampin (600 mg daily for 7 days before and after rolapitant) decreased the maximum concentration and AUC of rolapitant (180 mg single dose) by 30% and 85%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4-mediated rolapitant metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Varubi (rolapitant) [prescribing information]. Waltham, MA: Tesaro Inc; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9799":"<p><b>Title</b> Pimozide / Rolapitant</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rolapitant may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of pimozide and rolapitant. This combination is listed as contraindicated in rolapitant prescribing information.</p> \n<p><b>Discussion</b> Rolapitant prescribing information states that its use in combination with pimozide is contraindicated.<sup>1</sup> The suspected primary mechanism of interaction between these agents is rolapitant inhibition of CYP2D6-mediated pimozide metabolism, which could increase pimozide exposure and the risk of QT prolongation and/or torsades de pointe. Based on a study with dextromethorphan, a single 180 mg dose of rolapitant moderately inhibits CYP2D6 on the day of dosing and continues beyond 28 days post-dose.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Varubi (rolapitant) [prescribing information]. Waltham, MA: Tesaro Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}